<SEC-DOCUMENT>0001129928-19-000044.txt : 20190813
<SEC-HEADER>0001129928-19-000044.hdr.sgml : 20190813
<ACCEPTANCE-DATETIME>20190813160911
ACCESSION NUMBER:		0001129928-19-000044
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20190630
FILED AS OF DATE:		20190813
DATE AS OF CHANGE:		20190813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		191020702

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>q22019form6-k.htm
<DESCRIPTION>2019 SECOND QUARTER 6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s960492C26E9D52D684D475A613D85E9E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;  </font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">Form 6-K</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Foreign Private Issuer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Rule&#160;13a-16 or 15d-16</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the month of&#160;August </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission File Number 001-38512</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Translation of registrant&#8217;s name into English)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite&#160;210, 1167 Kensington Crescent NW</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Calgary, Alberta, Canada T2N 1X7</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Address of principal executive offices)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:20%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form&#160;20-F&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#254;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form&#160;40-F&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font><font style="font-family:inherit;font-size:10pt;">&#32;Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note:</font><font style="font-family:inherit;font-size:10pt;">&#32;Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s4C1FA3201DDD5EC5946E3C95A74E138A"></a></div><div style="line-height:174%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCORPORATION BY REFERENCE</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Registrant&#8217;s Management&#8217;s Discussion and Analysis of Operations and Financial Condition for the Three and Six Months Ended June 30, 2019, included as Exhibit&#160;99.2 of this Form&#160;6-K and the Interim Financial Statements as of and for the Three and Six Months Ended June 30, 2019, included as Exhibit&#160;99.1 of this Form&#160;6-K (Commission File No.&#160;001-38512), furnished to the Commission on&#160;August 13, 2019, are incorporated by reference into the Registrant&#8217;s Registration Statement on Form&#160;F-10 (Commission File No. 333-224432).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:82%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NUMBER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex991-interimfsjun302019.htm"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech&#174; Inc. June 30, 2019 Interim Financial Statements</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex992-q22019mda.htm"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech&#174; Inc. June 30, 2019 Management Discussion &amp; Analysis</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex993-q22019certificationx.htm"><font style="font-family:inherit;font-size:10pt;">Certification of June 30, 2019 interim filings - CEO</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex994-q22019certificationx.htm"><font style="font-family:inherit;font-size:10pt;">Certification of June 30, 2019 interim filings - CFO</font></a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:4%;"></td><td style="width:3%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August 13, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;Kirk Look</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kirk Look</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-interimfsjun302019.htm
<DESCRIPTION>2019 SECOND QUARTER INTERIM FINANCIAL STATEMENTS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4DBE00EA41045CCFB1A6B7E7EBE04DF1"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interim Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;color:#000000;text-decoration:none;">2018</font></div><div><br></div><hr style="page-break-after:always"><div><a name="sD1A8A5016B025F03A587AB0F3308FE81"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:536px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:304px;"></td><td style="width:40px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,<br>2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,<br>2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,275,766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,699,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">44,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,024,205</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700,986</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,344,249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,452,517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">345,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,736</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-of-use assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">612,765</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">957,920</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412,736</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15,302,169</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities And Shareholders&#8217; Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current Liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,094,184</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,825,853</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">927,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,322</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">372,895</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,467,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,814,575</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-current liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,887</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,428</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">316,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total non-current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,047,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,855,315</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;font-style:italic;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,514,221</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,669,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and contingencies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share capital<br>&#160;&#160;Authorized: unlimited<br>&#160;&#160;Issued:<br>  June 30, 2019 &#8211; 20,359,295 <br>  December 31, 2018 &#8211; 17,399,749</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">292,611,439</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,193,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contributed surplus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">28,752,377</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,260,613</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">482,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">607,504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(321,675,987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(311,483,385</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total shareholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,787,948</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15,302,169</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="sED7522D1872054829045DA9E8EAE5A33"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:656px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:246px;"></td><td style="width:60px;"></td><td style="width:82px;"></td><td style="width:4px;"></td><td style="width:82px;"></td><td style="width:4px;"></td><td style="width:83px;"></td><td style="width:4px;"></td><td style="width:84px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6, 13, 14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,508,948</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,045,417</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,705,868</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,980,308</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Operating</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6, 13, 14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,800,260</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,638,802</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,592,072</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,401,355</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before the following</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5,309,208</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,684,219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(10,297,940</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,381,663</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Interest income, net</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">55,357</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">105,338</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,428</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5,253,851</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,663,681</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(10,192,602</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,334,235</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(547,758</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(547,878</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5,253,851</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,211,439</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(10,192,602</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,882,113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other comprehensive (loss) income items that may be reclassified to net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Translation adjustment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(65,522</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,029</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(124,955</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5,319,373</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,147,410</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(10,317,557</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,747,463</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.26</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.53</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.58</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Weighted average number of shares (basic and diluted)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">7</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,181,112</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,406,944</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,308,364</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,191,457</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s8401FF136E625E648A7D9E310A82F4D2"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:883px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:260px;"></td><td style="width:73px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:95px;"></td><td style="width:4px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:86px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Capital</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contributed Surplus</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Deficit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,710,138</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,028,238</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373,730</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(294,446,160</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,283,846</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,882,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,747,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,606,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,606,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,269</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,359</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,910</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696,210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696,210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,451,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,451,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,458,995</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,710,089</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">508,380</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303,328,273</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,966,761</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">As at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,193,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,570</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,260,613</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">607,504</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(311,483,385</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss and other comprehensive income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,192,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,317,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,343</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69,343</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Common Stock Purchase Agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,562,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,562,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,974,059</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,974,059</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">561,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">561,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187,632</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187,632</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As at June 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">292,611,439</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">28,752,377</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">482,549</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(321,675,987</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,787,948</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sC648B1630BCF58EEBDC6441E2BA6CE31"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:680px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:296px;"></td><td style="width:57px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:78px;"></td><td style="width:4px;"></td><td style="width:76px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5,253,851</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,211,439</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(10,192,602</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,882,113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25,369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">73,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - right-of-use-assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3, 13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90,906</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">181,679</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6, 13, 14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">260,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">561,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">696,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense on lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">28,163</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">48,577</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">30,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">114,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(102,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in non-cash working capital</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">70,389</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,720,317</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,078,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,227,770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash (used in) provided by operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4,748,578</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">589,264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,134,269</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,019,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investing Activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition of property and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,660</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash used in investing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6,894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,443</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,660</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80,062</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing Activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,910</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,910</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from Common Stock Purchase Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,529,672</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from "At the Market" equity distribution agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,147,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,819,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from public offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,188,526</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,188,526</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(98,897</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(222,802</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash provided by financing activities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,048,206</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,213,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,126,232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,734,168</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Decrease) increase in cash</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,707,266</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,765,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,017,697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,634,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,213,811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,745,255</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,699,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,836,119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of foreign exchange on cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(230,779</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(406,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,616</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,275,766</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,741,347</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,275,766</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,741,347</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s20639EE39C9A5BE28DFD338A3C302B1F"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDF34BFA3ECD2547881DEF107E89F4280"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 1: Incorporation and Nature of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd.  On April 8, 1998, we changed our name to Oncolytics Biotech Inc.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our interim consolidated financial statements for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">August&#160;2, 2019</font><font style="font-family:inherit;font-size:10pt;">. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Markets and the Toronto Stock Exchange. Our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics.  Our lead product, pelareorep, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep emphasizes three programs: chemotherapy combinations to assist the escape of the virus from the vasculature and enhance its distribution in the tumor; immuno-therapy combinations to create an inflamed phenotype promoting synergies with immune checkpoint inhibitors; and immune modulator/targeted combinations to upregulate natural killer cells promoting synergies with targeted therapies. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s295C4CBB6ECF524AB85E4B22D8DEF09A"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 2: Basis of Financial Statement Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our interim consolidated financial statements include our financial statements and the financial statements of our subsidiaries as at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and are presented in Canadian dollars, our functional currency.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our accounts are prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB"). The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These interim consolidated financial statements have been prepared in compliance with International Accounting Standard 34 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interim Financial Reporting.  </font><font style="font-family:inherit;font-size:10pt;">The notes presented in these interim consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements.  Accordingly, these interim consolidated financial statements should be read in conjunction with our most recent annual audited consolidated financial statements, for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. We have consistently applied the same accounting policies for all periods presented in these interim consolidated financial statements as those used in our audited consolidated financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, except for the adoption of new standards effective as of January 1, 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s534E216E146A54448C88C348114FAEEC"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 3: Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Adoption of New Accounting Standards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IFRS 16 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IFRS 16 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IFRS 16&#8221;) replaces IAS 17 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;IAS 17&#8221;) and related interpretations for annual periods beginning on or after January 1, 2019. We have adopted IFRS 16 using the modified retrospective approach, under which the cumulative effect of the initial application is recognized in retained earnings at January 1, 2019. We have not restated comparatives for 2018. On transition to IFRS 16, we elected to apply the following practical expedients: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Applied the exemption for short-term leases that have a remaining lease term of less than 12 months as at January 1, 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Excluded initial direct costs for the measurement of right-of-use assets as at January 1, 2019; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Relied upon our assessment of whether leases are onerous under the requirement of IAS 37, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Provisions, contingent liabilities and contingent assets</font><font style="font-family:inherit;font-size:10pt;">&#32;as at December 31, 2018 as an alternative to reviewing our right-of-use assets for impairment; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measured the right-of-use assets at an amount equal to the lease liability, adjusted by the amount of lease incentive liability related to that lease recognized in the statement of financial position immediately before the date of initial application. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On transition to IFRS 16, the Company recognized $882,437 of lease liabilities. Lease liabilities have been measured by discounting future lease payments using the Company's incremental borrowing rate at January 1, 2019 as rates implicit in the leases were not readily determinable. The weighted-average rate applied is 15%. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the impacts of adopting IFRS 16 on the consolidated financial statements:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:40%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact of changes</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As reported as at December 31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effects of IFRS 16 transition</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent to transition as at January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,673,278</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,750</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,412</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,338</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882,437</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current and non-current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,556,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,669,890</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">808,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,477,915</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total shareholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to adopting IFRS 16, our total minimum operating lease commitments as at December 31, 2018 were $961,575. The difference between the total of the minimum lease payments set out in Note 11 of our 2018 annual consolidated financial statements and the total lease liabilities recognized on transition was a result of the effect of discounting on the minimum lease payments.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Explanatory information </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our portfolio of leases consists of office spaces. We currently do not have leases with variable lease payments, residual value guarantees, extension or termination options, or leases not yet commenced to which we are committed to. Our total undiscounted lease liability as at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.94736842105263%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:69%;"></td><td style="width:30%;"></td><td style="width:1%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity analysis - contractual undiscounted cash flows</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less than one year</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One to five years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343,805</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">More than five years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total undiscounted lease liability as at June 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">791,266</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting policy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At inception of a contract, we assess whether a contract is, or contains a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the contract involves the use of an identified asset;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we have the right to direct the use of the identified asset. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A right-of-use asset and corresponding lease liability is recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Significant Judgments, Estimates and Assumptions</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make judgments in determining whether a contract contains an identified asset. The identified asset should be physically distinct or represent substantially all of the capacity of the asset, and should provide us with the right to substantially all of the economic benefits from the use of the asset.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also make judgments in determining whether or not we have the right to control the use of the identified asset. We have that right when we have the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decisions about how and for what purpose the asset is used are predetermined, we have the right to direct the use of the asset if we have the right to operate the asset or if we designed the asset in a way that predetermines how and for what purpose the asset will be used.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make judgments in determining the incremental borrowing rate used to measure our lease liability for each lease contract, including an estimate of the asset-specific security impact. The incremental borrowing rate should reflect the interest that we would have to pay to borrow at a similar term and with a similar security.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s75071C8983495AB09E268736FF0BA49A"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 4: Cash Equivalents </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of interest bearing deposits with our bank totaling $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">11,269,477</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9,977,409</font><font style="font-family:inherit;font-size:10pt;">).&#160;&#160;The current annual interest rate earned on these deposits is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.97%</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;(</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.71%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5C248FFE69445DE5BD489BDA5E0F1ED6"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 5: Share Capital</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlimited number of no par value common shares</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Consolidation:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2018, we completed the consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, 9.5 warrants issued in 2017 will entitle the holder to purchase one whole common share until June 1, 2022.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:665px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:293px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued:</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,805,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,710,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">519,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,269</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, May 22, 2018 - pre-consolidation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,396,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,268,722</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, May 22, 2018 - post-consolidation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,988,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">272,268,722</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,445,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,900</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to public offering</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(b)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,606,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to warrant agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to stock option plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,297</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,751</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Common Stock Purchase Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,314,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,002</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,360</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,333,474</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,399,749</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,193,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,617,570</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to incentive share award plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to Common Stock Purchase Agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(c)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,390,372</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,562,608</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued pursuant to "At the Market" equity distribution agreement</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(d)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,543,829</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,974,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(187,632</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, June 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20,359,295</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">292,611,439</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,617,570</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million which allowed us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace&#8221; (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). During the period ending June&#160;30, 2018, we sold 519,500 pre-consolidation shares (approximately 54,682 post-consolidation shares) for gross proceeds of $553,650. We incurred share issue costs of $33,335.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 5, 2018, pursuant to an underwritten public offering, 1,532,278 common shares were sold at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">1,379,024</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">) common shares for gross proceeds of US$</font><font style="font-family:inherit;font-size:10pt;">2,663,768</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">) and issued </font><font style="font-family:inherit;font-size:10pt;">11,348</font><font style="font-family:inherit;font-size:10pt;">&#32;commitment shares (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">). The commitment shares have been valued at fair value of US$</font><font style="font-family:inherit;font-size:10pt;">21,998</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">) and have been recorded as share issue costs in addition to cash share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">3,757</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">). </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over a 19-month period through the facilities of the Nasdaq Capital Market in the United States. During the period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">1,543,829</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">) for gross proceeds of US$</font><font style="font-family:inherit;font-size:10pt;">2,984,586</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">). We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">154,697</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">nil</font><font style="font-family:inherit;font-size:10pt;">).</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding warrants at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:9px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:100px;"></td><td style="width:4px;"></td><td style="width:102px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:90px;"></td><td style="width:4px;"></td><td style="width:134px;"></td><td style="width:4px;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, Beginning of the Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Granted During the Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercised During the Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding, End of the Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,443,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;(1) Exercisable into </font><font style="font-family:inherit;font-size:8pt;">1,730,894</font><font style="font-family:inherit;font-size:8pt;">&#32;common shares.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB534221B41125E1FAD1C26F0DF3E1BCE"></a></div><div style="line-height:120%;padding-top:1px;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 6: Share Based Payments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Stock Option Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:655px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:214px;"></td><td style="width:99px;"></td><td style="width:4px;"></td><td style="width:112px;"></td><td style="width:107px;"></td><td style="width:4px;"></td><td style="width:112px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,249,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">647,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,867</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.38</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited during the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.33</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,578</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">29.07</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised during the period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.20</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,245,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.70</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">913,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.54</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">841,965</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">666,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:3px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.35</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the stock options outstanding and exercisable at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:683px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:182px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td><td style="width:100px;"></td><td style="width:96px;"></td><td style="width:4px;"></td><td style="width:100px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.66 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">711,827</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">447,494</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.25</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$4.84 - $7.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">333,251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">193,607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.18</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$13.77 - $19.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">92,308</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16.94</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">92,308</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16.94</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.23 - $36.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32.39</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$38.09 - $63.84</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">58,357</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50.85</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">58,357</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50.85</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,245,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.70</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">841,965</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10.69</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-exercisable options vest annually over periods ranging from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options issued during the period was determined using the Black Scholes Option Pricing Model using the following weighted average assumptions and fair value of options: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:449px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:273px;"></td><td style="width:90px;"></td><td style="width:85px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.88%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected hold period to exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility in the price of the Company's shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84.11%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rate of forfeiture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.67%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average fair value of options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.04</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incentive Share Award Plan</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Share Units</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have issued restricted share units ("RSUs") to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;year period. The following RSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:511px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:325px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">260,755</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,407</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Granted during the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested during the period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(23,240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">256,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,298</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:36px;"><font style="text-align:justify;font-family:inherit;font-size:8pt;padding-right:24px;">(1)</font><font style="font-family:inherit;font-size:8pt;">The weighted average fair value of the RSUs granted was </font><font style="font-family:inherit;font-size:8pt;">$2.33</font><font style="font-family:inherit;font-size:8pt;">&#32;in </font><font style="font-family:inherit;font-size:8pt;">2019</font><font style="font-family:inherit;font-size:8pt;">&#32;(</font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;">&#32;- </font><font style="font-family:inherit;font-size:8pt;">$6.27</font><font style="font-family:inherit;font-size:8pt;">).</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Share Units</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also issued performance share units ("PSUs") to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;">&#32;or vest over a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:511px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:325px;"></td><td style="width:88px;"></td><td style="width:4px;"></td><td style="width:88px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">63,156</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,734</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Forfeited during the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested during the period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,105</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">61,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,156</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have reserved </font><font style="font-family:inherit;font-size:10pt;">2,035,930</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs was $</font><font style="font-family:inherit;font-size:10pt;">260,184</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$561,107</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three and six month periods ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively (</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- $</font><font style="font-family:inherit;font-size:10pt;">157,092</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$696,210</font><font style="font-family:inherit;font-size:10pt;">, respectively).  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s23BE94CEE34E53CBBD7E83A9F953BCB0"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 7: Loss Per Common Share</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the three and six month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">20,181,112</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">19,308,364</font><font style="font-family:inherit;font-size:10pt;">, respectively (June 30, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;- </font><font style="font-family:inherit;font-size:10pt;">15,406,944</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15,191,457</font><font style="font-family:inherit;font-size:10pt;">, respectively). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s592ED97275D55373B5D0B4ABB534B8DA"></a></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 8: Contract Liability and Receivable</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Regional licensing agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrant purchase agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also entered into a warrant purchase agreement with Adlai. As at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we were entitled to the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One common share purchase warrant of US$6 million whereby, upon exercise, Adlai may purchase our common shares priced at a 20% premium to the five-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant upon the enrollment of the 50th patient in the phase 3 metastatic breast cancer study. This common share purchase warrant expires on November 14, 2020. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contract liability</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">Our contract liability balance, which w</font><font style="font-family:inherit;font-size:10pt;">e expect to record in revenue over the next </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:443px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:236px;"></td><td style="width:102px;"></td><td style="width:4px;"></td><td style="width:96px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,<br>2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,<br>2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,182,580</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regional licensing agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized in the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">927,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability - non-current</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,730,287</font></div></td><td style="vertical-align:bottom;border-bottom:1.5px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2D80B6223A595E5380B547EAF0A59E49"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 9: Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to payments totaling </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4,562,437</font><font style="font-family:inherit;font-size:10pt;">&#32;for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next year. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">&#32;plus an overhead repayment of </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">, upon sales of a specified product.&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of gross sales of a specified product; or (b) </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum once sales of a specified product commence.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8E6CB2D339CF5F20870D7B022220B51F"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 10: Capital Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection.&#160;We include shareholders&#8217; equity and cash and cash equivalents in the definition of capital.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:72%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,<br>2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,<br>2018<br>$</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,275,766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,699,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,787,948</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,195,363</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and lease liabilities, and we have potential contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf  provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Base Shelf allowed us to enter into our Common Stock Purchase Agreement in September 2018 and our ATM equity offering sales agreement in October 2018 (see Note 5). We will use these equity arrangements to assist us in achieving our capital objective. Each arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5B7074094DAE5B079306DF4B11F95368"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 11: Financial Instruments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents,&#160;other receivables and accounts payable.&#160;&#160;As at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.&#160;In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities.  As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;">$45,891</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the British pound against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">by approximately </font><font style="font-family:inherit;font-size:10pt;">$1,787</font><font style="font-family:inherit;font-size:10pt;">.  The impact of a </font><font style="font-family:inherit;font-size:10pt;">$0.10</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the value of the Euro against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;">$26,666</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:596px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:197px;"></td><td style="width:133px;"></td><td style="width:133px;"></td><td style="width:133px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US dollars </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-align:center;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-align:center;">&#163;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro<br>&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,804,404</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,724</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,392</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,172,556)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,848)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(290,556)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,631,848</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(258,164)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 10. Accounts payable are all due within the current operating period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1AB9355CED4B5AC99477D2B1C0A3854A"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 12: Additional Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change In Non-Cash Working Capital</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:369px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:74px;"></td><td style="width:4px;"></td><td style="width:74px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,899,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,767,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,418</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,826</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,372</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,988</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(903,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(402,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1,323,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(313,149</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">861,895</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(204,913</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,268,331</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(687,585</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(19,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(39,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash impact of foreign exchange</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">124,007</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">165,827</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,315</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in non-cash working capital related to operating activities</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">70,389</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,720,317</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,078,973</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,227,770</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Cash Flow Disclosures</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:591px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:342px;"></td><td style="width:58px;"></td><td style="width:4px;"></td><td style="width:58px;"></td><td style="width:4px;"></td><td style="width:58px;"></td><td style="width:4px;"></td><td style="width:58px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash interest received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">83,520</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,538</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">153,915</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,428</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash taxes paid</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,376</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,752</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,376</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,752</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><a name="s44624C03004153E89421DA03E07FC9A1"></a></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ONCOLYTICS BIOTECH INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2019</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 13:  Other Expenses and Adjustments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We present our expenses based on the function of each expense and therefore include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash stock based compensation associated with research and development activity as a component of research and development expenses and depreciation of property and equipment, depreciation of right-of-use assets and non-cash stock based compensation associated with operating activities as a component of operating expenses.  </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:679px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:294px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:91px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in research and development expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Realized foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,505</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized non-cash foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">93,908</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(161,862</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">237,369</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(236,996</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">99,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">223,599</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330,509</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Included in operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25,369</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,126</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">73,707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,984</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - right-of-use-assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">181,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">161,076</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,541</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">337,508</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,701</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s34B584E415D7599E9B786D521F2AB4EE"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Note 14:  Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Compensation of Key Management Personnel</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.   </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:643px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:273px;"></td><td style="width:91px;"></td><td style="width:4px;"></td><td style="width:86px;"></td><td style="width:4px;"></td><td style="width:87px;"></td><td style="width:4px;"></td><td style="width:87px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Month Period Ending June 30, 2018<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Month Period Ending June 30, 2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term employee compensation and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">674,231</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">445,493</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,378,020</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">956,555</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">234,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">503,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">486,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">908,933</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">565,360</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,881,821</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,443,237</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992-q22019mda.htm
<DESCRIPTION>2019 SECOND QUARTER MD&A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5C25B99092E358419416A14C9FD766F2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;"><img src="oncolyticslogobluea05.jpg" alt="oncolyticslogobluea05.jpg" style="height:290px;width:665px;"></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT DISCUSSION &amp; ANALYSIS</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:16pt;font-weight:bold;">&#32;</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s4BF894A1F9135E149B9175C9AA886A57"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;color:#000000;font-weight:bold;text-decoration:none;">August&#160;2, 2019</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This discussion and analysis should be read in conjunction with the unaudited interim consolidated financial statements of Oncolytics Biotech</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Inc. as at and for the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and and should also be read in conjunction  with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) contained in our annual report for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD82E210BBA775D48AAF8E4C485FC2E5E"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and under applicable Canadian provincial securities legislation.  Forward-looking statements, including our belief as to the potential of pelareorep, an intravenously delivered immuno-oncolytic virus, as a cancer therapeutic and our expectations as to the success of our research and development, clinical and manufacturing programs in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the forward-looking statements made within this MD&amp;A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investors should consult our quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements.  We do not undertake to update these forward-looking statements except as required by applicable law.</font></div><div><a name="s9DDE4D525E83565991BDB5C92808B3D6"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Pelareorep Development Update For </font><font style="font-family:inherit;font-size:16pt;color:#000000;font-weight:bold;text-decoration:none;">2019</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oncolytics Biotech Inc. is a Development Stage Company</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company. We have focused our research and development efforts on the development of pelareorep, an intravenously delivered immuno-oncolytic virus (IOV) with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal each year is to advance pelareorep through the various steps and stages of development required for potential pharmaceutical products.  In order to achieve this goal, we believe that we have to actively manage the development of our clinical trial program, our non-clinical and collaborative programs, our manufacturing process and pelareorep</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">supply, and our intellectual property.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s47823A8B463C5D79A813E21FF1BFBEE9"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical development plan, based on drug combinations that can potentially boost each response of pelareorep's mechanism of action, has two main objectives: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The primary objective is to obtain regulatory approval as quickly as possible and is based on our compelling metastatic breast cancer survival data presented at the 2017 AACR Annual Meeting. Using these survival data as the basis for our registration program, we may advance pelareorep directly into a phase 3 trial under a 2018 agreement with the United States Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA). In an effort to increase the likelihood of success in the planned phase 3 program, we first have undertaken studies to define a biomarker that may allow us to more cost-effectively and more quickly enroll patients into the phase 3 trials and to populate the study with patients more likely to respond to therapy.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The second objective is to expand the commercial potential of pelareorep by testing its capacity to boost the effectiveness of valuable new treatments, including immunotherapies like checkpoint blockade.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">Second Quarter </font><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">2019</font><font style="font-family:inherit;font-size:14pt;font-style:italic;font-weight:bold;">&#32;Developments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Clinical studies aiding registration program</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc.: BRACELET-1 study </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2019, we entered into an agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody, for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative (HR+ / HER2-) mBC. The cost of this phase 2 clinical trial will be shared equally between Oncolytics and Pfizer. The study, known as BRACELET-1 (</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BR</font><font style="font-family:inherit;font-size:10pt;">east c</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A</font><font style="font-family:inherit;font-size:10pt;">n</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CE</font><font style="font-family:inherit;font-size:10pt;">r with the Oncolytic Reovirus Pe</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">L</font><font style="font-family:inherit;font-size:10pt;">areor</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">E</font><font style="font-family:inherit;font-size:10pt;">p in Combina</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">T</font><font style="font-family:inherit;font-size:10pt;">ion with anti-PD-L1&#160;and Paclitaxel), is an open label study that will enroll 45 patients into three cohorts with 15 patients per cohort: paclitaxel alone, paclitaxel in combination with pelareorep and paclitaxel in combination with both pelareorep and avelumab.&#160;The study will examine the expression of immune-related biomarkers to identify changes in T cell clonality between pre-treatment and on-therapy biopsies to confirm our previously identified biomarker and is designed to assess efficacy in terms of overall response rate at week 16 per RECIST 1.1 and iRECIST. The safety of the combination will also be evaluated.&#160;Similar to the AWARE-1 study (see below), the results of this study may provide an opportunity to add an arm to our proposed phase 3 study that includes a checkpoint inhibitor in addition to the chemotherapy-virus combination. Furthermore, the results of the BRACELET-1 study will provide important confirmatory data in the same patient population where we presented compelling metastatic breast cancer survival data at the 2017 AACR Annual Meeting. These endpoints, including the biomarker data, are expected to further de-risk our planned phase 3 registration study, permitting for a smaller study with a higher likelihood of clinical success.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration with SOLTI: AWARE-1 study</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, we announced a collaboration with SOLTI, an academic research group dedicated to clinical and translational research in breast cancer. This clinical collaboration, AWARE-1, is a window of opportunity study in the neoadjuvant setting for breast cancer using pelareorep in combination with F. Hoffmann-La Roche (Roche)'s anti-PD-L1 checkpoint inhibitor, atezolizumab (Tecentriq</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">), which we are utilizing under our Master Clinical Supply Agreement with Roche. The study plans to enroll 38 patients. Data generated from this study is intended to confirm that the virus is acting as a novel immunotherapy in breast cancer and to confirm biomarker data for breast cancer. The primary objective of this study is to supplement the existing randomized phase 2 results by providing key biomarker data points to enhance our probability of success in the phase 3 registration study. The results of this study may also provide an opportunity to add an arm to our proposed phase 3 study that includes a checkpoint inhibitor in addition to the chemotherapy-virus combination. In February 2019, we received approval for AWARE-1 from the Spanish Agency for Medicine and Health Products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2019, we announced that the first patient was treated. We expect to announce interim data from the study in the second half of 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Additional checkpoint inhibitor combinations </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pancreatic cancer study combining pelareorep and Keytruda</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup>&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, we announced the first patient had been treated in our investigator sponsored study (IST) supported by Merck Inc. (Merck), Northwestern University along with Oncolytics. This study, an extension of our phase 1 study (REO 024), will investigate pelareorep in combination with Merck&#8217;s anti-PD1 checkpoint inhibitor Keytruda</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, to treat second line pancreatic cancer patients. The study plans to enroll approximately 40 patients. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2019, we continued patient enrollment and treatment. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Multiple myeloma study combining pelareorep and Opdivo</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup>&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, we announced that the first patient had been treated in our IST with Emory University and the University of Utah investigating the combination of pelareorep and Bristol-Myers Squibb's anti-PD1 checkpoint inhibitor Opdivo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;in 40 - 50 relapsed or refractory myeloma patients.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2019, we continued patient enrollment and treatment. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Non-clinical/Research collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In April 2019, the following presentation was made describing</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">analysis of patient samples from REO 024:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:14%;"></td><td style="width:16%;"></td><td style="width:15%;"></td><td style="width:55%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Presenter</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Location</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description/Conclusion</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exploratory analysis of T cell repertoire dynamics upon systemic treatment with the oncolytic virus pelareorep in combination with pembrolizumab and chemotherapy in patients with advanced pancreatic adenocarcinoma</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grey Wilkinson, PhD, Translational Scientist, Oncolytics Biotech Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">American Association for Cancer Research (AACR) Annual Meeting 2019, Atlanta, Georgia&#160;</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Data presented in the poster demonstrated:</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Patients treated with pelareorep in combination with chemotherapy and pembrolizumab showed changes in their T cell repertories with high turnover and significant expansion during treatment;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">These post-treatment expanded T cell populations, are "new" clones not present at baseline, suggesting effective priming of the immune system;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Higher T cell clonality at baseline correlates with longer progression free survival (HR=0.05, p=0.01) and overall survival (HR=0.12, p=0.01) demonstrating the predictive value of the assay;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Enhanced T cell clonality after the first cycle of treatment correlates with improved overall survival (HR=0.08, p=0.01) and serves as an on-treatment prognostic biomarker;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Early expanded T cell clones, detected at day 8 of treatment (prior to pembrolizumab), most strongly correlate with survival time which suggests that early versus late clonal expansion may be elicited by pelareorep treatment; and</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">T cell clonality has significant potential as a predictive and prognostic on-treatment biomarker to pelareorep therapy.</font></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2019, the following abstract was published highlighting additional immune-based biomarker data used to help predict patient response to pelareorep in combination with checkpoint inhibitor therapy:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:14%;"></td><td style="width:16%;"></td><td style="width:15%;"></td><td style="width:55%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Author</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Location</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description/Conclusion</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC)</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Christos Fountzilas, Assistant Professor, Dept. of Medicine - GI Medical Oncology, Roswell Park Comprehensive Cancer Center</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">American Society of Clinical Oncology (ASCO) 2019 Annual Meeting</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key data and conclusions demonstrated:</font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Clonal T cell diversity was expanded during therapy, broadening the potential repertoire of T cells that can target tumor cells;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">~30% of expanded clones at day eight of pelareorep therapy were durable after one cycle of treatment suggesting a refinement of T cell clones that target the best tumor cell antigens;</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Gene expression analysis in peripheral blood mononuclear cells (PBMCs) helps to validate the changes in T cell diversity, where responding patients had higher levels of pro-inflammatory cytokines expressed by activated T cells, compared to non-responders. Importantly, there was a statistically significant upregulation of genes that aid in the recruitment and activation of T cells including IL17F, CCL7, and ICOS (raw p &lt; 0.05); and</font></font></div><div><div style="float:left; width:24px; padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8211;</font></div><font style=""><font style="font-family:inherit;font-size:10pt;">Gene expression analysis in PBMCs may serve as a separate and independent biomarker, and helps to corroborate our previously published blood-based T cell clonality biomarker for pelareorep therapy.</font></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Post Q2 2019 Development</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2019, we announced preliminary AWARE-1 trial data demonstrating viral replication and promotion of inflammation following systemic administration of pelareorep when combined with Tecentriq</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. Early data suggest a correlation between T cell clonality and viral replication with highly infected tumors. We have also received favorable recommendation from the Steering Committee to advance into the next phase of the AWARE-1 study. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s43CA686BD7C1591C80DC61EF4393D62B"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Manufacturing and Process Development </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2019, as we continued our production of 100-litre cGMP batches, we supplied our clinical development program with previously filled product from our existing stock of pelareorep, labeled for the applicable usage. As well, we continued our activities to develop clinical and commercial production capabilities to fill pelareorep into vials, the next step in the process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of the Company&#8217;s submission to regulators, including the FDA, for product approval. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s204ECC1BA7C75EE389AFFAF293491A7C"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the end of the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;">398</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;">48</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028.  Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s328BFC203E515D6AAC65EE870F3A0FF8"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financing Activity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. "at-the-market" equity distribution agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">1,300,245</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for gross proceeds of US$</font><font style="font-family:inherit;font-size:10pt;">2,448,925</font><font style="font-family:inherit;font-size:10pt;">. We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">116,663</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s76C98170897257B69E0F3DFD913B566B"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Impact</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimated at the beginning of the first quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;that our cash requirements to fund our operations for the year will be between $19 - $23 million. We now expect our cash requirement for 2019 to be between $19 - $20 million, depending on our ultimate clinical program. Our cash usage for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was $</font><font style="font-family:inherit;font-size:10pt;">8,134,269</font><font style="font-family:inherit;font-size:10pt;">&#32;for operating activities and $</font><font style="font-family:inherit;font-size:10pt;">9,660</font><font style="font-family:inherit;font-size:10pt;">&#32;for the acquisition of property and equipment. Our net loss for the period was $</font><font style="font-family:inherit;font-size:10pt;">10,192,602</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s521FA9AF091153BF8106E8122CEEC414"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Cash Resources </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We exited the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;with cash and cash equivalents totaling </font><font style="font-family:inherit;font-size:10pt;">$12,275,766</font><font style="font-family:inherit;font-size:10pt;">&#32;(see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s50D821DC2A415A27AD84949B47FC91DA"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Pelareorep Development for the Remainder of 2019</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our planned 2019 development activity for pelareorep focuses on our clinical development plan along with our manufacturing and intellectual property programs. Our 2019 clinical objective is to incorporate our immuno-oncology combination strategy that includes checkpoint inhibitors and confirming the existence of a biomarker as we finalize our registration strategy and clinical protocol in preparation for a phase 3 clinical study in mBC. We expect to commence clinical trial site selection and initiation activities and first patient enrollment in our multiple myeloma study combining pelareorep with Keytruda</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Velcade</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and dexamethasone. We will continue enrollment in our AWARE-1, REO 024 extension and Opdivo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">combination studies. With respect to BRACELET-1, we expect to select a principal investigator, complete regulatory filings and commence clinical trial site selection and initiation activities in anticipation of first patient enrollment by the first quarter of 2020. Our expectation is that these combination studies will assist us in refining our phase 3 protocol for mBC and may also support further development around the innate and adaptive immunity components of the mechanism of action. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our 2019 manufacturing program includes preparation for continued production of 100-litre cGMP batches along with the related analytical testing and product filling, as well as labeling, packaging and shipping of pelareorep to our various clinical sites for ongoing and upcoming activities. These actions also contribute to progression through our process validation master plan. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently estimate the cash requirements to fund our operations for 2019 will be approximately $19 - $20 million, but will depend on our ultimate clinical program (see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Liquidity and Capital Resources&#8221;</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5FBCE7D4F67E57088335C6FEA12EBA42"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Second Quarter Results of Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(for the three months ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the three month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$5,253,851</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$4,211,439</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three month period ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:544px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:384px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">443,874</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">813,555</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,020,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">136,459</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,712</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">35,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,681</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">673,980</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">699,425</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange gain</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">99,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">99,108</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,551</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,508,948</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,045,417</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.8828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">443,874</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">813,555</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trial expenses for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$443,874</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$813,555</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">. Our clinical trial program activities related primarily to the preparation and development of our breast cancer registration study. In the second quarter of 2019, these costs included patient enrollment and treatment for our AWARE-1 study, costs to complete </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our supporting regulatory documents and key opinion leader activities. In the second quarter of 2018, these costs included phase 3 startup activities and activities related to obtaining the Special Protocol Assessment from the FDA. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarters of 2019 and 2018, in addition to activities related to our breast cancer program, we also incurred close out costs related to our fully enrolled legacy clinical trials</font><font style="font-family:inherit;font-size:10pt;color:#ee2724;">&#32;</font><font style="font-family:inherit;font-size:10pt;">and costs related to patient enrollment and/or treatment in our checkpoint inhibitor pancreatic cancer study investigating Keytruda</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">in combination with pelareorep. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development Expenses (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.90625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,975,391</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,609</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">45,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,020,630</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,066</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our M&amp;P expenses for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$2,020,630</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$441,066</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">. During the second quarter of 2019, our product manufacturing costs primarily related to an engineering production run and shipping and storage costs of our bulk and vialed product. During the second quarter of 2018, our product manufacturing costs included shipping and storage costs of our bulk and vialed product along with startup costs for a product fill required to support our clinical development plan. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development expenses for the second quarter of 2019 focused on analytical development and for the second quarter of 2018 focused on analytic development and stability studies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">136,459</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,712</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$136,459</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$183,712</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">. The change in intellectual property expenditures reflects the timing of filing costs associated with our patent base. At the end of the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;">398</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;">48</font><font style="font-family:inherit;font-size:10pt;">&#32;US and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaboration Expenses </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">35,857</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,681</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research collaboration expenses were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$35,857</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$37,681</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">. Our research collaborations during the second quarter of 2019 and 2018 included studies investigating the interaction of the immune system and pelareorep. Our research collaborations during the second quarter of 2018 also included biomarker studies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">606,466</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">640,710</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">67,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Research and Development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">673,980</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">699,425</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Other Research and Development expenses were </font><font style="font-family:inherit;font-size:10pt;">$673,980</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$699,425</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. The change in our R&amp;D salaries and benefits was mainly due to the timing of filling open positions in our U.S. office. Our Other R&amp;D in the second quarter of 2019 expenses remained consistent with the second quarter of 2018.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Exchange Loss (Gain)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">99,040</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159,573</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our foreign exchange loss was </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:normal;">$99,040</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;compared to a gain of </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:normal;">$159,573</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">. The foreign exchange loss incurred in the second quarter of 2019 was primarily due to unrealized translation loss on U.S dollar denominated cash balances, partly offset by unrealized translation gain on U.S. denominated accounts payable. The foreign exchange gain incurred in the second quarter of 2018 was primarily due to the fluctuation in the U.S. dollar exchange rate on the translation of U.S. currency received from our June 2018 public offering and the settlement of our contract receivable.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">99,108</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,551</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based payment expenses for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were $</font><font style="font-family:inherit;font-size:10pt;">99,108</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">29,551</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. We incurred share based payment expenses associated with the vesting of granted options and share awards to officers and employees. In the second quarter of 2018, we also recognized a recovery of share based payment expenses due to the departure of the former Chief Medical Officer and the forfeiture of unvested share awards and options.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:537px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:377px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">798,605</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">777,321</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">724,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">712,814</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25,369</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,126</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">90,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">161,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,541</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,800,260</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,638,802</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating expenses for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$1,800,260</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,638,802</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. Our public company related expenses were $</font><font style="font-family:inherit;font-size:10pt;">798,605</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">777,321</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. The change in our public company related expenses in the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was due to an increase in investor relations and business development activities, and an increase in insurance premiums, partly offset by lower professional fees. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), rent related to short term leases and other office related costs. During the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, our office expenses were $</font><font style="font-family:inherit;font-size:10pt;">724,304</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">712,814</font><font style="font-family:inherit;font-size:10pt;">&#32;for the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. The change was primarily due to a change in salary levels, partly offset by a reduction in office rent expense following the adoption of IFRS 16 with an increase in depreciation of the newly created right-of-use assets (see Note 3 of our interim consolidated financial statements). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash share based payment expenses in the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were $</font><font style="font-family:inherit;font-size:10pt;">161,076</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">127,541</font><font style="font-family:inherit;font-size:10pt;">&#32;in the second quarter of </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. We incurred share based payment expenses associated with the vesting of granted options and share awards to officers, employees and non-employee directors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s078816A85AC751038B55CBE743DC1E81"></a></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(for the six month period ending </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$10,192,602</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$8,882,113</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.     </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:544px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:384px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:75px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,271,052</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,846,300</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,940,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">858,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenditures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">605,832</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">590,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaboration expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">70,833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,349,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,411,276</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange gain</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">244,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(284,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">223,599</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330,509</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,705,868</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,980,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Clinical Trial Program</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:376px;"></td><td style="width:75px;"></td><td style="width:4px;"></td><td style="width:68px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trial expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,271,052</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,846,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trial expenses were </font><font style="font-family:inherit;font-size:10pt;">$1,271,052</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,846,300</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. Our clinical trial activities related primarily to the preparation and development of our breast cancer registration program. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, these costs included startup activities and patient enrollment and treatment for our AWARE-1 study as well as costs to complete our supporting regulatory documents and key opinion leader activities. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, these costs included phase 3 startup activities and activities related to obtaining the Special Protocol Assessment from the FDA. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, in addition to activities related to our breast cancer program, we also incurred close out costs related to our fully enrolled legacy clinical trials and patient enrollment and/or treatment in our checkpoint inhibitor pancreatic cancer study investigating Keytruda</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">in combination with pelareorep. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our clinical trial expenses to increase in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. For the remainder of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we expect to generate clinical data with checkpoint inhibitors, confirm the existence of a biomarker and commence study initiation activities related to BRACELET-1. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing &amp; Related Process Development (&#8220;M&amp;P&#8221;)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.3203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:71%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product manufacturing expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,828,834</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637,312</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Process development expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">111,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and related process development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,940,735</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">858,769</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our M&amp;P expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$2,940,735</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$858,769</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, our product manufacturing costs primarily related to the completion of training and engineering production runs as well as shipping and storage costs of our bulk and vialed product. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, our product manufacturing costs included shipping and storage costs of our bulk and vialed product along with startup costs for a product fill required to support our clinical development plan. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our process development expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$111,901</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$221,457</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, our process development activities focused on analytic development studies. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, our activities focused on analytic development and stability studies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our M&amp;P expenses for </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;to increase compared to </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. In </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we expect to fill, label and store sufficient product as well as continue to perform analytical development and other non-clinical projects to support our clinical development program and other collaborative requirements. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:74%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">605,832</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">590,227</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$605,832</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$590,227</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.  The change in intellectual property expenditures reflects the timing of filing costs associated with our patent base. At the end of the first half of </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we had been issued over </font><font style="font-family:inherit;font-size:10pt;">398</font><font style="font-family:inherit;font-size:10pt;">&#32;patents including </font><font style="font-family:inherit;font-size:10pt;">48</font><font style="font-family:inherit;font-size:10pt;">&#32;U.S. and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;Canadian patents, as well as issuances in other jurisdictions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect that our intellectual property expenses will remain consistent in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaborations</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:76%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research collaborations</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">70,833</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,728</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research collaboration expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$70,833</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$227,728</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. During the six month periods ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, our research collaborations included studies investigating the interaction of the immune system and pelareorep. Our research collaborations during the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;also included biomarker studies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect that our research collaborations will remain consistent in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. We expect to complete our ongoing collaborative program carried over from 2018 and will continue to be selective in the types of new collaborations we enter into in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research and Development Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D salaries and benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,239,024</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,300,870</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other R&amp;D expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">110,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Research and Development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,349,759</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,411,276</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Other Research and Development expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$1,349,759</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,411,276</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The change in our R&amp;D salaries and benefits was mainly due to the timing of filling open positions in our U.S. office. Our Other R&amp;D expenses for six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;remained consistent with the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We still expect our Other R&amp;D expenses will remain consistent in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Exchange Loss (Gain)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange loss (gain)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">244,058</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(284,501</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our foreign exchange loss for the six month period ending</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">was</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$244,058</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">compared to a gain of</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$284,501</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">for the six month period ending</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">. The foreign exchange loss incurred during the six month period ending</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">was primarily due to unrealized translation loss on U.S dollar denominated cash balances, partly offset by unrealized translation gain on U.S. denominated accounts payable. The foreign exchange gain incurred during the six month period ending</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to the fluctuation in the U.S. dollar exchange rate on the translation of U.S. currency received from our June 2018 public offering and the settlement of our contract receivable. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Based Payments</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:518px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:378px;"></td><td style="width:68px;"></td><td style="width:4px;"></td><td style="width:62px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">223,599</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330,509</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, our non-cash share based payment expenses were </font><font style="font-family:inherit;font-size:10pt;">$223,599</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$330,509</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. We incurred share based payment expenses associated with the vesting of granted options and share awards to officers and employees. In the second quarter of 2018, we also recognized a recovery of share based payment expenses due to the departure of the former Chief Medical Officer and the forfeiture of unvested share awards and options.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.9296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:70%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018<br>$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public company related expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,565,925</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,584,580</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,433,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,410,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">73,707</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,984</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation - right-of-use assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">181,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share based payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">337,508</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,701</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,592,072</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,401,355</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operating expenses for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were $</font><font style="font-family:inherit;font-size:10pt;">3,592,072</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to $</font><font style="font-family:inherit;font-size:10pt;">3,401,355</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our U.S. and Canadian stock listings. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, our public company related expenses were </font><font style="font-family:inherit;font-size:10pt;">$1,565,925</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,584,580</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The change was due to lower professional fees, including legal fees and costs related to the special meeting of shareholders held in February 2018, partly offset by increased investor relations and business development activities as well as increased insurance premium.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office expenses include compensation costs (excluding share based payments), rent related to short term leases, and other office related costs. During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we incurred office expenses of </font><font style="font-family:inherit;font-size:10pt;">$1,433,253</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$1,410,090</font><font style="font-family:inherit;font-size:10pt;">&#32;during the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The change was due to a change in salary levels and an increase in our U.S. headcount, partly offset by a reduction in office rent expense following the adoption of IFRS 16 with an increase in depreciation of the newly created right-of-use assets (see Note 3 of our interim consolidated financial statements). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, our non-cash share based payment expenses were </font><font style="font-family:inherit;font-size:10pt;">$337,508</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$365,701</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;for the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. We incurred share based payment expenses associated with the vesting of granted options and share awards to officers, employees and non-employee directors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We now expect our operating expenses to increase in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. We expect to continue to grow our investor relations and business development activities and to continue to invest in our U.S. operations in support of our clinical development program.  This increase is expected to be partly offset by a reduction in office rent expense following the adoption of IFRS 16 with an increase in depreciation of the newly created right-of-use assets (see Note 3 of our interim consolidated financial statements).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we are committed to payments totaling approximately $</font><font style="font-family:inherit;font-size:10pt;">4,562,437</font><font style="font-family:inherit;font-size:10pt;">&#32;for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next year. All of these committed payments are considered to be part of our normal course of business. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s976652EBBF0B52D796780036C27CE67C"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Summary of Quarterly Results</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:647px;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:246px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td><td style="width:9px;"></td><td style="width:36px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="6" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td colspan="12" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td colspan="6" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mar</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mar</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dec</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sept</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,254</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,939</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,819</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,336</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,211</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,671</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,746</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,004</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,302</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,461</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,865</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,848</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash dividends declared</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nil</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:8pt;">.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The calculation of basic and diluted loss per common share for all periods has been adjusted retrospectively for the share consolidation on May 22, 2018. Included in net loss and loss per common share between June 2019 and July 2017 are quarterly share based payment expenses of </font><font style="font-family:inherit;font-size:8pt;">$260,184</font><font style="font-family:inherit;font-size:8pt;">, $300,923, $483,016, $236,607, $157,092, $539,118, $140,659 and $148,447, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We issued 2,934,201 common shares for net cash proceeds of 7.3 million in </font><font style="font-family:inherit;font-size:8pt;">2019</font><font style="font-family:inherit;font-size:8pt;">&#32;(</font><font style="font-family:inherit;font-size:8pt;">2018</font><font style="font-family:inherit;font-size:8pt;">&#32;- 2,472,909 common shares for net cash proceeds of $13.3 million).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">We have not declared or paid any dividends since incorporation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><a name="s860C46AB93C45D05812BC9B5527F1F09"></a></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;"><br></font></div><div><a name="s7EB4640FD9E058A1B3B9D6070EDC5E86"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share Consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2018, we completed the consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share. Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, 9.5 warrants issued in 2017 will entitle the holder to purchase one whole common share until June 1, 2022.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">&#32;Financing Activities </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Purchase Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">1,379,024</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for gross proceeds of US$</font><font style="font-family:inherit;font-size:10pt;">2,663,768</font><font style="font-family:inherit;font-size:10pt;">&#32;and issued </font><font style="font-family:inherit;font-size:10pt;">11,348</font><font style="font-family:inherit;font-size:10pt;">&#32;commitment shares. The commitment shares have been valued at fair value of US$</font><font style="font-family:inherit;font-size:10pt;">21,998</font><font style="font-family:inherit;font-size:10pt;">&#32;and have been recorded as share issue costs in addition to cash share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">3,757</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. "at-the-market" equity distribution agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;During the six month period ending </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we sold </font><font style="font-family:inherit;font-size:10pt;">1,543,829</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares for gross proceeds of US$</font><font style="font-family:inherit;font-size:10pt;">2,984,586</font><font style="font-family:inherit;font-size:10pt;">. We incurred share issue costs of $</font><font style="font-family:inherit;font-size:10pt;">154,697</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4195562EBF765A44893D90056F87DD32"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">2018</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">&#32;Financing Activities </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Listing on the Nasdaq Capital Market</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2018, we announced that our common shares were approved for listing and commenced trading on the Nasdaq Capital Market. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public offering</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 5, 2018, we closed a public offering whereby we sold 1,532,278 post-consolidation common shares at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Canadian "At-the-Market" equity distribution agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six month period ending June 30, 2018, we sold 519,500 pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for net proceeds of $520,315. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Options</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2018, we received cash proceeds of $23,910 with respect to the exercise of 71,000 pre-consolidation options (approximately 7,473 post-consolidation options) by a former employee.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2018, we received cash proceeds of $1,417 with respect to the exercise of 1,500 warrants.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s553FEEBD27965B6793D0D591E9B9F253"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents and working capital positions as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:66%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30,<br>2019<br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,<br>2018<br>$</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,275,766</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,699,881</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital position</font></div></td><td style="vertical-align:middle;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,877,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;border-bottom:3px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,637,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any debt other than trade accounts payable and lease liabilities, and we have potential contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares. Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to 150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renewing our Base Shelf  provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Base Shelf allowed us to enter into our Common Stock Purchase Agreement in September 2018 and our ATM equity offering sales agreement in October 2018 (see Note 5 of our interim consolidated financial statements). We will use these equity arrangements to assist us in achieving our capital objective. Each arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that the expected cash usage from our operations in 2019 will be between $19 - $20 million. We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources. Additional activities continue to be subject to adequate resources and we believe we will have sufficient cash resources to fund our presently planned operations to the end of 2019. Factors that will affect our anticipated cash usage in 2019, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&amp;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2019.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCAB093DA24F95DF0A6ED7F61DA6FA6C0"></a></div><div style="line-height:120%;text-align:left;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Financial Instruments and Other Instruments</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments consist of cash and cash equivalents, other receivables and accounts payable.  As at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, there are no significant differences between the carrying values of these amounts and their estimated market values. These financial instruments expose us to the following risks:</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is the risk of financial loss if a counter-party to a financial instrument fails to meet its contractual obligations.  We are exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada. For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates. We are exposed to interest rate risk through our cash and cash equivalents. We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Currency risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities. As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$45,891</font><font style="font-family:inherit;font-size:10pt;">. The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$1,787</font><font style="font-family:inherit;font-size:10pt;">. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net loss in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;by approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$26,666</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We mitigate our foreign exchange risk  by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.  </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balances in foreign currencies at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.5703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:63%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">US</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">dollars <br>$</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">British pounds</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#163;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8364;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,804,404</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,724</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,392</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,172,556</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,848</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(290,556</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,631,848</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(258,164</font></div></td><td style="vertical-align:bottom;border-bottom:3px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in Note 10 of our interim consolidated financial statements. Accounts payable are all due within the current operating period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5FBFC2D5DA455C28B89B739819F8B610"></a></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Other MD&amp;A Requirements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">20,390,316</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding at </font><font style="font-family:inherit;font-size:10pt;">August&#160;2, 2019</font><font style="font-family:inherit;font-size:10pt;">.  If all of our options, restricted share units and performance share units (</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,580,611</font><font style="font-family:inherit;font-size:10pt;">) and common share purchase warrants (</font><font style="font-family:inherit;font-size:10pt;">1,730,894</font><font style="font-family:inherit;font-size:10pt;">) were exercised or were to vest, we would have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">23,701,821</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;annual report on Form 20-F is available on www.sedar.com.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s38266A0943DC576AB3E601138F3A9903"></a></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disclosure Controls and Procedures</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no changes in our internal controls over financial reporting during the quarter ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;that materially affected or are reasonably likely to materially affect, our internal controls over financial reporting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ex993-q22019certificationx.htm
<DESCRIPTION>Q2 2019 CERTIFICATION CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sACA29929D7E9513D9212C1C831146BE1"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FORM&#160;52&#8209;109F2</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">I, Matthew Coffey, President and CEO of Oncolytics Biotech Inc., certify the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Review:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;I have reviewed the interim financial report and interim MD&amp;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended </font><font style="font-family:inherit;font-size:11pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">No misrepresentations:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Fair presentation:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Responsibility:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&amp;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="font-family:inherit;font-size:11pt;">, for the issuer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-48px;"><font style="font-family:inherit;font-size:11pt;">designed DC&amp;P, or caused it to be designed under our supervision, to provide reasonable assurance that:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-96px;"><font style="font-family:inherit;font-size:11pt;">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-96px;"><font style="font-family:inherit;font-size:11pt;">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-48px;"><font style="font-family:inherit;font-size:11pt;">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Control framework:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div></td></tr></table><div><br></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ICFR &#8209; material weakness relating to design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;N/A.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Limitation on scope of design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;N/A.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Reporting changes in ICFR:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The issuer has disclosed in its interim MD&amp;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on January 1, 2019 and ended on </font><font style="font-family:inherit;font-size:11pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:11pt;">&#32;that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;August 13, 2019&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:47%;"></td><td style="width:6%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/s/ Matthew Coffey</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Matthew Coffey, PhD, MBA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">President and CEO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>ex994-q22019certificationx.htm
<DESCRIPTION>Q2 2019 CERTIFICATION CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCB6B2A3204B356D49B30ED9D07362BAB"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FORM&#160;52&#8209;109F2</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">I, Kirk Look, CFO of Oncolytics Biotech Inc., certify the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Review:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;I have reviewed the interim financial report and interim MD&amp;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended </font><font style="font-family:inherit;font-size:11pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:11pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">No misrepresentations:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Fair presentation:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Responsibility:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&amp;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="font-family:inherit;font-size:11pt;">, for the issuer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-48px;"><font style="font-family:inherit;font-size:11pt;">designed DC&amp;P, or caused it to be designed under our supervision, to provide reasonable assurance that:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-96px;"><font style="font-family:inherit;font-size:11pt;">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:96px;"><font style="font-family:inherit;font-size:11pt;">(ii)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-96px;"><font style="font-family:inherit;font-size:11pt;">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:11pt;text-indent:-48px;"><font style="font-family:inherit;font-size:11pt;">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.1</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Control framework:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div></td></tr></table><div><br></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.2</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ICFR &#8209; material weakness relating to design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;N/A. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">5.3</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Limitation on scope of design:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;N/A.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Reporting changes in ICFR:</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;The issuer has disclosed in its interim MD&amp;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on January 1, 2019 and ended on </font><font style="font-family:inherit;font-size:11pt;">June&#160;30, 2019</font><font style="font-family:inherit;font-size:11pt;">&#32;that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: &#160;&#160;&#160;&#160;August 13, 2019&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:47%;"></td><td style="width:6%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/s/ Kirk Look</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Kirk Look, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">CFO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>oncolyticslogobluea05.jpg
<TEXT>
begin 644 oncolyticslogobluea05.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
M 00# 0$!            ! $" P4)"@L(!P;_Q !W$  ! @,#" <$ PD(# H%
M A<  0(#! 4&$2$'$C%!46%Q\ @3@9&AL=$)"L'A%"+Q%1HR-U=V=[6V%B,X
M0E)REM49,S0V5F)T=967LK,7)"4G<X*2TM/6-4-3M]08)BA$1564HN)&1U1G
MA<)C96:3M&2&IL7&_\0 ' $!  (" P$               <( 08"! 4#_\0
M6!$!  (! @(%!0@+#0<#! (#  $" P01!2$&!Q(Q01,B46%Q(S(U0G)S@;,4
M%S-24V)TD9.AL14D-$-4@I2RP<+1TM1C@Y*BM-/P%J/A1%7#\25DA*1%_]H
M# ,!  (1 Q$ /P#O\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    "EXO!NJ"GAW"[?Y>@8W]2H*"Y#&XJ"EZ;A>)M#*H
M!2]#$6W\)"_FY1?S<HO07H9W]7[&.?\ Y'_R7\W*+^;E%Z"]!OZOV'/_ ,C_
M .2\J4O0K>8FWJED *7H(M J"F&X7&=Q4%+M_D+N/@98W]2H*7[A>&=U0
M
M
M
M
M
M
M
M
M
M                                                    *7@W5!07
M+M&[&ZMY2\7)L**Y-IC<YK@8UB)J\KRQ7KJ^*> W_P#/_(99;N;U*\[3!G+M
M[N? 8[5&T^G]1LRJ].5*=8GV8\_88KA>-ADZS<OD.LW>)CO*9Z&1?G+RJ_84
MO7[$N\2Q7IW&/KDY2[S,;1Z!GQVJ4[5YX&#K>/A\!UBZD\53T,FS/<+DV&#.
M?J3GB,Y^SP#.W_F\,]R;!<FPP9S]G@,Y^SP!M_YO#/<FP7)L,&<_9X#.?L\
M;?\ F\,]R;!=SH\C!G/V> SG[/ &W_F\,]W-ZE<=JD;/=L\5*];Q\/B@8V2+
MUV]^(SEW>*>"&!(O."^5Q>V(BI?\#&WJ9V9NL79XE>LW+X&+/3:5OYN,[,,O
M6(51Z;N_[##>@N,;"0BE+N;U,";E4K>NWOQ,;3Z?U&R04,.>O*KY:_B7)$37
MY7&9&2_<+RB/3:5N39X#=CFJ"EW. ,[FZH*7E0SN
M
M
M
M
M
M
M
M
M
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M HB"\1(J!>#(
M
M
M
M
M
M
M
M
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M 1TPT<\[4,C8FA%OO\!#&S(BE2V\8\J(G<7 I>5,L@
M
M
M
M
M
M
M
M
M                                                     !15N*8X
M["HW84YT%<-QC6)LQ,:WKIY]3CW^IG9>Z)LQ+555T@QNB(AR@7Z"CG7&#.5U
M]WPY].)8B(N_G;Q R.BKJQ\/#CV%MR_QEO2_0F)7PW)]F)9G(G/H&=UR(F-R
M<_ 8;>=)A=$OT<_#G@6[-?;\>>X,,JQ-G/;PT%F>O#G?CV&-5PX]_?Z:BBOV
M)SSX 53GY:[MX<J;4^)B55V\\[RQ7ISCY<W 9E?S\_EH*9R\.=Y'<]>'B8W/
MVK=SW]NK5@!)5=JW]ICZSF[U]/,P*_=SYZC&L1>'C\N[#P E=;P[^?0M6(NU
M"&L7??V_)"Q8J;.]4 E9Z<>]?0IG[$3GAS=<0UB\I>OF6*_F_P! )W6;T3N+
M%B?XV[3\B$K^&O3\RU8J)K^&J_4@$Q7IQVX\]UQ;UB;/(A=;>FC3K^U2BQ.<
M )W6<$[>?0IUO#GL(#HFS'O^ ZSAX_%>=($_K5YY0IUJ\I\R!G[53N3U+>M3
M^5=W>@&QZU=OA\RJ1%VIW?,UO6;U"Q4_E+SV ;+K%VIW?,IUR\I\S7=:G\I;
MN=PZS8J^'H!L>M7E/F52(O*7&MZU/Y78OV%R1$V^"<_8!L.MYY0KUO\ -[5-
M=UB[4[OF5ZS'=V_$#8=8FSR*H].5P\-! ZSF]/0JC]W/?SH V*1/\;Q^6XR)
M$7:G@:QL9+NWG2G-Q?GIJN^/@O.P#8Y_#GP^-Q5'IPYVH0$>G*W<^15(G'S\
M>;@-BV)A@J>?H9$B+N[.>=1K4BIN7G?\#)UB<.==P$](G.KU+FN34MW!?D06
MQ-F/.['FY,+S(D3=SV\]H$Y'+MOX^I7/VIW8^B_ A([?V?+AJ[=)D:];^?CI
M EYR+K2_?SWE5YY7'G:1NLW7%Z+L7T DHY4T+?N]>&XO2)MY^*>)&1RZTOWE
MZ.1;]&.WF].P"5@NOQ"Z-O.[7]I'NX^?/-Y5'JF^[G3Z^0&?7AAAN3E=/<7)
M$5-/?S@8TB(I<F[NU=P9W9FOY7G[2\C+=LN\N?+ )>B;MG./H&$E,-&!<D3;
MW\Z/(P-C(IE10,]Z+L*\Z"/=LP+TB7:4[=7R..VWK-F6]"I1%O**BZC,2Q,K
M@ 99
M
M
M
M
M
M
M
M
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M^1E:^_48[O6,@+;BZ\S$@ #(
M
M
M
M
M
M
M
M
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MNN^XS7HN\P(H3#1MUX_8<9CZ!(0J8FOON37@7W;+NXSNPN!1%*F60
M
M
M
M
M
M
M
M
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M6];C,8F-QFTE;R.WZO#GGR,S7(O?P,3.WL%X+;^=A5%.1NJ
M
M
M
M
M
M
M
M
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MCD;=FW)>BJO5! GJVX-_(_\ W]1_9FABO6CQV/\ Z[\^GTL__@=O&E>\_P!
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M7JW1BG.'$D-?>FKE PSL?M+T0CW%[7ZEY2XXSR&5'(I4L71@OCP+D4S$[BH
M,@
M
M
M
M
M
M
M
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MM9=I[ML5-]I]62^.4:\:ZW.%Z;>N"<FMR1X88[.+?GRG-DVCZ<=,D.^5E_\
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MS'/>&&="I1<?D#,2PJ #+(
M
M
M
M
M
M
M
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M9GUH;XGQG5ZV_E-7J,NHMX>4M,UK\BGO*1ZJ5K$>A;F(7(5!Z;S
M         MSD!NN!3.07[O(QNQNJ"E^[R*9R<!N;PN!;GIM+KS+(
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MRSL=FZ=W/.@SD<JUUW"_PY[DP.,QXQWL,R+\BXI@I1%,UG=CN_L7  RR
M
M
M
M
M
M
M
M
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MK6E8]E:Q$>WT]\H2U>LRY\ELN?+DS9+SO;)DO-[S[;6F9Y>'HCEW  .RZX
M       8NLQT*8F3=E!2&CGQ&0FM<^*_\"$QJOC/_F0FHL1^&IK56['&X^PL
MCOL^LMUODAQ+*9+[85&5BYN949BEOH])<KKKD^ZM;6G4]%N5'*BS**C/K79N
M)UM3KL.&O:S9<>*OWV6]<=?^*\Q'ZW9TNBS9[=C!ARYK_>XL=\EOS4K,OCQ7
M7%N?SSZ'/_DK]W)RWUI&1K2U>Q5C(+U:CH<S49JT-0AWHBN6))T> V5N;@ES
M*I$SW(Y$S6HCG<C>3/W9>P\JD*):[*5:FM/16];*T&E4RA2;TP5R0YN:?49Y
MF=<J)?#<C46_ZRI<:CK>L7A&"9B=77+,>&"M\N_LM2LX_P ]]FYZ#JSXUJ-I
MC1SBK/CGO3#MW=]+6\I_R3W2Z<N?S<I:Z88FES6[W.1/.Y/$]!;)W["WHU6?
MZM[["35HHT/-5L>U%HZS4G9Z+?G/@24>DR42^_%D64B0KO\ U=^)]NV#Z%62
M"R_5K9_)=8&DQ8>;FS$K92C?3/JW9JOG8LI$FXBI<ESHD=ZH[&^]5OU?5=<>
MBKOY'2ZG)Z[^3Q1/LF+9)_/6/8VS1]26OMMY?5Z7%$^&.,N:T1ZXFN*-_9:?
M:\SFS5B*Y6E:E&HM8JZN6YOW)I-1J><M^;<WZ!+3%ZYV%R7K?@?1EE.@7EMK
MB-6EY)LH,VU_X*K9>I2B+@U=%0A2BI^$GX2)INU+=Z9<I38$NB)+P($NB(B(
MDO @RZ-NP2Y(+(=UVJ[L)L17/_#B/?MSWN??OQ5;^T\'/US9I^Y:'%7YS-:_
M]7'C_:V33]1VGC;RO$,UY\?)X*8X_P":^5YU5$]C9TF9]$NR2U^214_^JLU1
MZ<J?6S+E2-455%_CW+_ZNY^A;C]6I7L#NDU-8NLE9V33K.K<L[;FS<!V:N:J
MQ$AI-/B/A-1;LYC555:Y&M5R'?Z;+-U-3L;C\[OGN,B0;M7ASSV'E9>M_B4^
M]PZ.O^[S3_\ G_L^AZN/J6X5'OLVNO\ [W#6/U8/[9=$&G>[N=(>*KDC,L))
MHU$5KHEKH$?K%55141)65BN:K4^M>]&MN6YJJM]VW^]TND!_^.6 _I+&_J\[
MU:0L-'F5ZO=YG5GK7XK_ /UH]F&?[<DS^MVHZF^#>C53[<\?V8XC]3HI_>Z7
M2 __ !RP'])8W]7FOJ'N[/2%AM1T%U@YIV<B+#AVK;!<C53%ZOF9.'#N3!,U
M'9RZM!WO.KW>8ZO<IB.M?BW_ /6_0?X7B?UGVF^#>C51ZXS\_P!=)C]3H%5?
MV 727E>L=#LU9:>:QK519.W5GE?$OTMAP(\:#&<YFN]J(NEJJB'Y77/8M=)J
MGYU^2VHSV:KD_P"2:I1*CG9K,^]G55!N<COP&*GX43ZEV<IZ(G4KL\-7#G L
M=+-UM3M2]/CXH=K%UN\3CWV+1V_W66/V9W7R]2_"I][EUU?][AM_6P;_ *WF
MCVL]G/EZH:.6JY(,H$KFWYUUGYB;NN1BK_Z/=.*N#V:+[[UNO5KD;\UVFR56
MJHN=]V;,6EHZ-2]RU:SU9IB-3#%RSTE+HC<47.543%+E5%13U3H;59^ YS-2
M9JJWRNYT(8IJ72/_ &]&S'^4,;'W?^M1^I+KMR7'J8.N;41]UT.&WS>6^/\
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M_4::W9U&#-@M][FQ7QSR]$7K&_T,(,:O5-2IMOP+VK@=N)=/=4 &0
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M><#,8"K77:=&/CHP\O'$XS'C'?\ M89T4J6Z>=?.DK>9B6%0 99
M
M
M
M
M
M
M
M
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M*9&NU*<)C;G##*"W!,>TJBG/<5
M
M
M
M
M
M
M
M                                        "BJ#=1<?L**MR?9JYYP*
MWW:N[@8'+>N[#GLV'#??V,0HBWXKV<\W![KD52JK<15=G+NT]FKM74AS94TW
MJNA-15=%ZZM&[=\]? KLU8<^'S,#WWX)X[.>=(9F5'N5;]B:T^&W<6.==Y(G
MCWA51+MR>>CM4PWW7JOV!A1[KKU7G5SMTZC ]5TKCSLY[BKW)??JYU>1$>[6
MO._U I$B:U[O7XD5RZ-=]Z;KM*X[$\2KHB8W[/+5OWJ0XC[]/.S#9L36!5[M
M//#LW:U(KW;?G?MXKHV=RE'OU\\;MO@0WQ+]?.SU 1(FGF[60GQ/LV[U*OB7
M[=W9BGR]2(^)=QY\-FT"L2)<B[>/.@A1(MZ[?BF'<EY9$B<[KM*_#>0WQ$WX
M^/9J3 "Z(_3MVZN'=H(;G[>>/IWEKW]_ESM^!"B1M-R_+G4!?%C:-NS1C?SP
MU$)S[M*X\Z.? M?$NWK\=_CPU'Q)TV.GOD_R$6=6MVQJ"Q*A-PXOW LQ3W0X
ME>M!,PT5,R2EW+=+R4.(F;-U:;S)&4^LF=&CYDM$[&DTF7/DIAPX[9,MY[-*
M4C>UI]4>J.<S/*(B9F8B'6UFLQ:?%?-GR4Q8L<=J^2\Q6M8]<SZ>Z(CG,S$1
M$S,0^G<I>4Z@6/HE0M):BL4^@T*E0'3%0JE3F&2TI+0DT9T1RYSXL1;F0)>"
MV),3$16PI>%$B.:U>F3[2GV\%HK??="QF2.)/V3L7$ZV4G[2WOE+56G@._>W
MLEG,=UEG*/'9>U8$%WW6G83U;-3$K!<Z4=QE].SVBF4++[7$GK3S?W/L[)1G
MQ*!8RFQHJ42CL6]K(\1KE1]4JSX:W3-6G$6,YRN9*PY277J3X):U;^=I87H=
MU9XM+V=1KHKFU/*U<7*V'!/?'JRY(],^96?>Q:8BZM73;K5S:SMZ7A\WP:6=
MZWS<Z9\\=T[>.''/WL;9+5]]-8FV-<V]555O55O557%555O555;[U5557*MZ
MN<JN555;S(@!+41LAV  &0    Q]8@W&0IG(?K^1+H_6URE5J%9RPEFJK:>K
MQ;E=*TR6=$9*PK\9FH33\R4ITJQ/K/F9V/ A-8BO1RHU53L[]#7W<.4E_HM:
MRWU_Z;%_>XO[B;)S3H<HQ<%6!6K3*Q(LS=>C8LO18,*#>US4J4U#B(]NM\=Z
M5Z'AU=]1FK%]MZX:>?FMZ-J1/*)\+7FE/QFS='^B'$.)VB-+@M./?:V>_F8*
M>G?),;6F/&F.+W_%=7O([D)MEE$K#*#8>S59M35GXK*4>3B3*P&*MW6S<Q]2
M4D("+@L>>F):!G7-ZS/5&KV.NB?[MO6)WZ/5,LEJH=%E_J1'63L=$A3]3>E]
M[H-1M#,PG4Z2O;<CF4Z4J$5JK$A+%@/1D8[5V27(M96P='@6>L;9RD68HLO=
MF4^C24*3@O<B(WKIA[46/.S#D:G63<['F9J(B)UD9^:EWZBV'NOP^5V[Q(1X
M]UKZS4=JFBI&CQ<_/GLY,]O#?>8[&/>/"M;6K/=DE//1[J=T.FVR:ZTZW+&T
M]CGCTU9]58GMY-I\;VBMH[\7@^4.C9T(LEF2.59 L!8NDT*81K6Q:SU*SUHI
MQ6WIGS5?GEF*G$=BMR,F(4-B.6&QC8=S4^K60DPXKV[]_;VDE(?V)SZ8&5L*
M[4B8\5YXX:R+]1J<F:\Y,N2^7);WU\EK7M/MM:9F?SI:TVFQX:5QX<=,6.O*
MN/'6*4K'HBM8B(^B$=L/==V<X_:AE2&FQ5V<^)(:Q-27W=IDS%T+AN\]_"[B
M?%]V!K-MVKS[N;R]&)Q71W\?302VP=B=_=SH,R2^B]>SG3Q\@(75+V%Z0<-:
MW\J;%D&[0FO7JX<Z3*V&NJ[L]= $!L!=EVC9SSWY$@[^[7MY^)/ZG;XJ96PE
M^Q/4#7M@HFI5YW]QD2%N3X]WP-@D';=VZN?F7-@[$3N7G?N @=7P[E\_B7)"
MXJ;%(*_+!.?D7)!X=MZ^7.K4!KNIW7=J)S\;MP2#S>J^7/<;1("ZD\/F7) 7
MAV)\0-7U/#N4=2FQ.Y3;=3N7L7X#J>/:X#4]2FQ.Y1U*;$[E-OU"[/\ [8I]
M'YP7Q U'4\WW?84ZGG.-NL!4^Q"WJ5V)W :E87%.=B<H6+"[>*<\Z<#;=2FQ
M.Y?/F\LZGG!>>=@&I6#NPW+\"Q8*;%3G=SP-MU*[$[E,?4[/!;O/E0-0L!$T
M+AL7GS+'0%NT(O/.PW#H2[.]#$L+AV:>[F\#3]3=AC?X<JFO3P,/5[/AJYTZ
M,#=.AK]J7]UQB=!OU8;@-,]FG#'=\MV!8L/9Y>G.HVRP-BW;ETW]I'= NU:]
M+>< -:L/L\O+O,*L[>'./-YLE8N-V[#7AX]R&%6;NWQ]>'@!KEAI\ODI^,9:
M^CU8C*+3%HUNK*T2U5.5+F0:S(0IJ)+*EZ-?)3BM2=D7PU<KH;I28A9C[GHB
MO1%/W5S%X[\/LN,/5_8O/<?3%EM2T7I:U+UG>MJ6FMJSZ8M$Q,3ZXE\\N&F2
MLTR5K>EHVM2]8M6T>B:S$Q,>J8=6?I8>[<T"?29J>1RU,Q9^:7.B,LK:Z)&J
M=(<N*]3)6@A-?59)-#83:G!J3$7ZT:=8W1UGNDMT,,IV2"?^@Y0+(U2A,?$Z
MN6JJP_I=!J"K>K?H%<E>MITPKVIGM@NBPIM&7.B2T-%N/3S?#VISQ]?F?S=I
M[)TZLR$S2ZQ3I"KTR<8L.;IM4DY:H2$U#72R8DIN%&EHS5_DQ(3DO1%2ZZ\D
MG@76EK]--:ZG;68HY3VY[.>(]66(GM>F?*5O:?OH19TAZHN':OM7TN^AS3O,
M>3CM8)GUX9F.S'S=J1'?V9>4LCDN["MYW6^F5[O+D_M=]*K&2J?_ .#NO1.L
MC?<282/4;&3L9UZYD."KHE4H*O=AGR46<E(><YWW/>U&0DZJ?2EZ#F4_(O44
MD+?V7FZ9+QHCF2%=EKJA9NJ(U43.I]:ED=*N>M[565F5E9YF>UD65AQ+X;9N
MZ/\ 370<1VKARQ3+MSP9=L>6/3V8F9KDCUX[6VC:;;=R!ND?07B/#)FV?#V\
M$=VIP[Y,/J[4[1;'OX1DK7>?>[][Y1!9GISI+D6\VW=I^ZH     8W)=HV\Z
M#( .5+V=_M:\H&06:@4G/BVKR=Q9A'3UCI^:<WZ V(Y.OF[+3L3/2CSJI]9T
MJJ/I4XYJ-CR\)ZI-0N])T4^E_8++-9J%:BP=;A5*63JX=2I\5&R]:H4X]N<L
MA6Z:YSHTG'1;^JB_7E)QB=;)S$:'?F>8,Y%/W#H[=(^VN2FT\G:ZPE<F:'6)
M549$="7K)*HRF<CHM.J\@]?H]2IT>ZZ+*S#5S5NBP'P9AD.*R-NF'5YI^(1;
M-@[.GUFV_;B/<\T^C-6O=:?PM8FW/SHO$1$2=T*ZR]3PR:X-1V]3H>4=F9WR
MX(].&T]]8C^*M/9GXDTF;3/J5M?MTI?==W^.SL)L.-CBN.U-?V>9PV>S4]KM
M8W+O*0*#4TE[*Y3)>!?.69C1_P#B5:ZMJ]=4+*3,9<Z<@JB=9&I,5?NG3T5<
M)N58DV[F$9%VX^2^FY=Z%;^)<,SZ/-;!J<=L66G?6W=,>%JS'*U9\+5F8GTK
M0\*XMI];@IJ-+EKFQ7[K5GG$^-;UG:U+U^-2T1:/&&[:^_9?W)L[MY+AOYV?
M+8IHX<6[7AY;/@;!L2_X+W<^!T'HMQ#B:._Y[EVDYD2_G'??SCJ-%#?HY3BB
M[B=#B^??QW@;MC\?/8I+AQ.=E^I=R^&!IX<2_G'G>2V.YV_- -TQ]_&[0NQ?
M-.;B3#?WW^6KT76F"FHAQ-'-R_%-WFA,:_#?KV77W:=:8 ;:$[L^S3\%)3']
MBZ?GSH-6QV._?AP[M2DIC\.><0-HQ]_/-Z>1(:Z_<N/A=SM-:U]_'3SQ3N3L
M)3':+M-_*=FK@!L&+??MY\-RZ"],+E[TV+?SY$9'7Z-/SYW&9JW\4P79MN[@
M)2+>G//-Q5?Y2:4NP].;B.CKN'BEW/IH)-^A4YO!$LT-UZ%Z[4TD55UIVIZ[
M[TPNUZ22UR*!F8Z]/#P#4N[>>?$PKACWDA%13A/+V?L)7 I>5.9$@
M
M
M
M
M
M
M
M
M   %$WE+\2US[M5^A._G$QNPL<^];D[>>'AO+0U+C%$?=@B<W<W;3,,K8CK\
M$QV\/M[2V_5J33JO^7.HHB78)KTKLPU<Z,2Q[[DNNO\ DN/=K^)@4>_4B]WC
MSJ,6V[5XKOW)?\2NY%QTJNQ%\;]M^@P.7N3F[G&\R"K>N/9]A&>Z_P ;MZZN
MS[2Z(Z]=W.'/S(KWX;K^>S7\@*.>F*]VKGFXBO=MYW(FTK$?C?W?/?PQU$1[
M_2[;M3MU@4B/QT\IJYT\-$-S]?<G.O8FHJ]Z8[$T=FCNT)=O(<6)SLWKOV;
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M+=]=XYJY\;X!J^'99PZO#;%;XMN_'DC[['DCS;QZ=IWKW6B+<EP /8>.
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MV'4'=;/45J-ZSZ1(->LMW+Z559><EY>;DX\":E)J!"F9::EHT./+S$O'8V)
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M"QUV'CQ7F\S*<8Y<A4! <@
M
M
M
M
M
M
M
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M*!*4S0W7\\\]I@8MZ(7(MRW[</F<;1N,^":RXMTW+P+CE
M
M
M
M
M
M
M
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MR A]7Q[D^'V;2G5KS>2\U-W/:,QN[GM A]7N[OE<6K#3^2I.ZM-OC>46'O\
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MV<W&9CKSC/*=Q>"U.WM+CD1(
M
M
M
M
M
M
M
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M;N=5_=@O#09W)>@$G@5,;'7\ZTY[2Y$N.-8VY?F]@N !R
M
M
M
M
M
M
M
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MYU#TO3GGM/IOH==+"TV16WM'MW9A^='D(BRU4I<2(Z')UZAS3F)4J+.HV_\
M>9N$UKH$96N=)SL*6FX:*Z"K'Z/TXZ)UXIIMJQ%=5AB;:?)/+>?C8KS]YDVC
MG\2T5MW1:+;WT"Z97X1JM[S:VCSS6NIQQSVY^;FI'W^/T?'IVJ]_9FOJ M>O
M:G/<O@3X46_R[4]<478A\^='+I!6;RH6-H5NK)3GTNBUZ428@9^:DS)S#%ZN
M=I=0AM5>HJ--F4B2LY"7!(C$BLSH$6$]_P"\,?K\-NCE2J>;#;'>V.]9I>EI
MK>MHVM6U9VM68\)B8VF/"5P,.:F2E,F.T7I>M;TO6=ZVI:(FMJS'*8F)B8GQ
MANH;KN=*;.S43X,31P\+L;]Z:MIIX3K^S%,=?K\.\FPHGX..O0FI=A\WU;V&
MMZ;TN[?M[K]Y-AOT;%NNUXHG/F::#$[]/;K3G7H-A#5,-^GR[-O<!N(;_'PY
MVDV&[1MNOT=R_!33PWZ=E^/#:;!C^].=6I=*< -K">GC]G<2V/T88ISY)@NW
M UC')=?MY\;KE)L-^*:[TY[+MP&Q8[7J^.KOU[%)2+<M^JZ[TT<?0U[':M2W
M+OOX^7<3&.OP78G//$"1=WI?=P1<>%R]Z$ECLY%YYW$1CM":T7GLN^=YE:N:
MN&C0B_#X7Z@,ZZEUI@OR)+'7H1T7QT[,-?P]2K%5JW<\KHVAE)1;EOU:.?B9
MM*&%2^&[3?XG&WI]'[&&5"I2\J<@
M
M
M
M
M
M
M
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MBQ33AO33Z+=K BJV_CY=W/ Q.9=IYX\W<-*3G-1;_!?CN\$,*I=IV:?7G1I
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M .3(
M
M
M
M
M
M
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M4%J+Y;"XR
M
M
M
M
M
M
M                                                           4
M"J+]IB9&"(M^&WR3YX;BBK\!IQYTJ8HSKD35CSV[#,##?>JKLQ^7Q"KFIWKS
MY!$P1-N*_#[-ACBXJB<.5Y^ &*_"]=+M*;OFN%YC5;UOV87[2]^A;MMS;TT7
M:/$C1,$N33CHV\WWKX; P/7!5V87=N*;_@F!$>Z["_%=*^-_P)$1VA-Z+Z=Z
M^&)#>Z]575QV>N'V 1W+L\-6[LT\2$];[]W?AH^9F>[GBNOCHVD%[O5?/ACH
MX)>!&B.T+P7=<FCM^) >[O\ +'!-WPNO,\1^W0MZKPT>&KP(3W8+J55U:N?/
M "/'B?''=]N&[M-;%?IWXJB=UW:2(K]O'L30B<XFMB.T[$7'G7ACQPT 8HKK
MO-=2;,/+=BIJWNTKJU+KOUK\"3&>NC7=HV<>=) BNXZ;KDO5=S41-*KL36H'
MROTT>E-1\C63BTN4"LYD5*1*=72J<YV:^L5Z<O@4:D0D2YRK-3=RS#FXP9&#
M-1__ %:(OFCY2\I-9ME:*MVKM%.OJ%=M#4YNK56<B+>L:<G(JQ(F:EZYD&$F
M; EH2?4@2T*# 8B,AM0YQ/;^=.!<H&4>'DUH,YUME,FT:- GGP(B.EJG;2/#
MZNJS%[?JQ8=#@*E&EW8I]*^Z<5CG,B07)P!,;=SO+.=671K["T?V1EKMJ-7%
M;SOWTP]^*GJFT3Y2W=/.M9C>BJ76KTJ^SM=]BXK;Z713:D;3YN34<HRW]$Q2
M8\E2>?*MK1.V1D !)B+   #8T6CSE2G9.G4Z5CSU0J$S+R4C)2L-T::G)R;B
ML@2LK+PF(KHL>8C/9"A,;BY[FIO35J[5<M_ [37N]WL]TGIIV7>UDC?*4^/,
MT_)S*3,/ZLS4(:++U.U:-=@^%3U=$I=(?H=/+/3;?JRL%T7P>D?'L7#M)EU.
M3:>S'9QT\<N6V\4QQ[9B9M//LTBUMIV>_P!&.C^7B>MQ:3%O':GM9<FV\8L-
M=NWDGN[HF(K'QKVK7>.UNYM?96^S^DL@V3N7I\Y#@1[<VD;+56VU1AHURLG>
MJOEJ!*Q<56G4!D1TLU47,FIY\Y/?@Q82,Y0&MU=Z[-?9?W(8X3+KKM-V'.I$
MVZ<27#9NUWKOW7;/+#:5!XAK\NJSY-1FMV\N6TWO;USW1$>%:QM6L=U:Q$1R
MA=/AO#L.DP8M-@IV,6&D4I6/1'?,SXVM.]K6GG:TS:><LD-NB_5W\KW$R%#O
M^*[+_6_ QPV*N*)N3GQX;S9,9A=KO2]?AMX'3=YD8S5JU:,5V>'>3H</!.;U
MV<]A9#AZ=6B_<FY-%^TV$*'HY1$T\[-&X#)"9Y]ZZ/ FL9HVZ]R7^?J6L;NW
M(G%-V[1X$V'#T<>]?3E *PH?R[-?IM)S&:DOWKLYVZBC&W7W)CIYX:DW$N&S
M1<G;HOOU<;](!C-2:.?#?KX$R'#U)L[MB^EV"%6,7?J\T^Q$V$EC-7?SY[-
M%6,U:MO;HW;]V@E,;?N3G1Z]Q1K+TPV^7/ DHFI$ M:EV"78<\Z3.C+K[L=^
MCGAK#6HB+NTKZ=F@O1BKP3SVKMV@43'!-&%Z[?ENV&9$N[>/*\ZB[!,$YWWE
M%79BNO=CAX@5<NV[ANW_ "+FLSL5PV)SMYN+F0[KE7G S7@$2X7A&JNI43G1
MSP,J-NY3GG>8F?SBB0]N/9A\RY%1,.=!787&-O3^;T"A4 Y
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M= D2&K@G!/(JBW+Q\[KKNTP0EQNV8=O.OL,Z@2%"*4:Y%T%;S$2*@ R
M
M
M
M
M
M
M
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MF(SUB1IB/&>^+&CQHCL7QHT5SHL5ZXN>YSEQ4QEJ-N+BVU8VC93;?T]X #(
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M,#COOW"FA, F\JB%3,1L  ,@
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MK@412IEF)
M
M
M
M
M
M
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M^DX=_L<9E33SX(7@',B/S@ #(
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MN.-HW@9DUEQ;\RXS$L0  RR
M
M
M
M
M
M
M
M    !1%"EJZ/#88EC=B?^$NZY?F8XBW(7)K7:O/.@QQEP1.=WCX8F8984T;W
M+X=FCXED==%V].>VZ\R:.Q+M^U>.XP.5%6_^2BZ-O9J2_2!C<MR*N"JGP^?B
M18F"7)NXWK?CQ\,<=1F=J3YZ/1?':87+>J;DOX?;Y(!%B+J3G4E_;CCA<08C
MM?=MNU?._2EQ*B+@J[51/A<0XB;D3?X<IJ AQ78;UONW;KOBG'408JHG!$\;
MD3OW=I)BNQNYW=V*[MY C/U]N.[1Q3&] (D5_A==JQUZ-5^L@Q5NPV)CMO\
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MXHA4Y00
M!;HX%P#$K'(BIRG/P,&A;E[.=IG1+MEV):YE^///.HX]WL_8RP/:BZC FG-6
M^^_!>>>TDHICB,PYVWG(8E1%P\".J7+=LT=N-RZM7P)"+KUW8\-'?N,3VWI>
MFGY\]VH".],45-F.'.KM(\1B:4W)V?+[2:BZ]5]R[UV_!2,J:MMZ^./CV*!
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M4B\J8X:WIW>GPO[2^\XUC85 !R
M
M
M
M
M
M
M
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M-7%9X*7K?CL3[=_ VC&ZMF'%=7K?Z$6"RZY=F''"]5NVZN)L(3?#'M7TU;\
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M.&TD,:B:$3F\"],"Z&E^E.'/EN+;KUNX7\%PY[C/H.-I\#=7@4:EQ5"IF(
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M#)"75L\M7=H7:9==_.DPM6Y>Q? D''Q8F  ')D
M
M
M
M
M
M
M
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M2XNAXK?Q\_LXB9&2&VY,>?D7IP**I<<:_M8  <F0
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MBWMK.UH]<1+T>$<1MI-7IM53OP9L>7;NWBMHF:SZKUWK/IB7K$PEXINUHO\
M&1=ER87;2? ?=CAA=?HX8>!^!=&W+'+90; V-MQ*/1\*U=G*16U7!%29G92&
M^>AN:W^UN9._26K#N18:(C51%0_>8?X5VW5HQ12EF;%;'>U+QM:EII:/1:L[
M6CZ)B87KPY:Y*5R4G>MZUO6?36T1-9^F)W;>&N_6BWZ$NT8<5U=ILH*ZNS1M
MQ2[<AJ(:X(O>NS5\.\V4);^-WBF_9OUWGS?1N8:Z%VI<NCOV$Z$[TX*FS:N&
MLUD.(MR>G;HW8FPAKINW+RG"_#:!MH;DP7<N/;RJDV&[5HPO1-6&/.W0:R&N
M";EV=J>%_#0MY/A+Z\]B^N" ;%B^';]N%_ FL79P3LQ1.*Z/(@0O@N'#Y8<"
M:S1O14W[L>SG ":Q,=R^G.\RM71PNO[,>U-2&-N"M[O R7K=P6_O39N E)=?
MCH5%3GGR*PL%NV+\M/<6WX7[%3R35VZ"Y'?6XW>=_/<!G=J78O@9TT<]YA70
MIF8N"+N&XN12I1-?'X(5#$2  ,@
M
M
M
M
M
M
M
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MIH:FJ[Y\.W$E(B(@!RZN;M9(1,.XQPT1;S*<9YSZC<0J <@
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M(U=#D7@J%YD                           !2\J     I>!4
M                       "\I>!4%+Q>!4%%<FU#"D6_0M_#'ROX@9P8<]=
MB]R^=UWP+U?AH6_@H%X,*O78MW#[0V*E]RJB+=HO0#,"EZ"\"H   I>5
M                              I>+T J"EY8^*B(N*)Q4#(#"UZK\DO^
M'-Y5'KK1>Y>= &4&)7+J\E]#&Z+=I5$XX;-NW'E )(+&O14TH77@5!2\J
M
M     "\7@       7@                               I>!4
M  I>!4                                     !2\J
M7@                                         "EX%04O%X%08'Q41?
MPD[TT]Y7/7>J;D7T[P,P+$?N7N7T*.?L1>Y?0#(# L14TX<4N3RP+V1$70J+
MVH!D O*7@5 O*7@5                            I>!4"\I>!4&)T5$N
MQ2^_1>@:]=?DO.@#*"W.3?W+Z%BN7?=P7GG:!E!'6-=IN39JO,R.1=:=Z 7
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M9
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MK%5L2&]KFKB;HKE,;<IC:8Y3'H6=B8F(F.<3SB8[ICU  ,,@
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MB8Y;3$]T^I(U;Q:(FLQ,3$3$Q.\3$]TQ,<IB?"85 !AR
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M_P 4??8.3C\E-N?]+6=_\4Z. 'VKN#?@,G](S?YS[;'&_P"4X_Z/@_R.\?\
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MC\E-N?\ 2UG?_%.CAMXKY@M%]J[@WX#)_2,W^=4O[;'&_P"4X_Z/@_R.\?\
M?8.3C\E-N?\ 2UG?_%'WV#DX_)3;G_2UG?\ Q3HX ?:NX-^ R?TC-_G/ML<;
M_E./^CX/\CO%1_>Q<G#(<2(N2BW2I#AQ(BI]UK.XI#8YZI_;=:-N.TEDYMG"
MM'0*)7X$&)+0:W2*75X,O&<QT6!"JDA+S\.#$<SZCHD)DPD-ZM^JKFJK?JJA
MX[%0_N:9_P FF?\ <1#UYNC!^+>P/YDV2_9VFD8]9/131<-QZ2VDQVI.6^6+
M]K)>^\4BDQ[^9V]]/<E?JNZ7Z[B=]7&LRUR1BKBFG9QX\>TVF^_O*UW[H[]W
M[J ")TP@                        *9R&-Z[].A-:Z\$TKMX 92EYQD],
MOVN.0W(<D:2M;:^7G[1PVWMLA9=K:[:.];\ULU*RL3Z-2K\%SJM-R;E8J1(4
M*,U#JS=*OWHC*G:%TS(9*;-TC)Y3'9[(-9J[(%J;5.8K<U(K84>&EG*?$OSG
M=6LE6$3ZMT5JWFV<%Z$<2U^UL6":8I[LV;W/'MZ:[QV[QZ\=+QZ6F<>Z?<+X
M=VJYM1&3-7E.#!MER[_>VB)BF.?5DO1WJK36LIE&E(M0JU1D:5(04OC3U2FY
M:1DH6E?WR:FXD&79@BK]:(F".6[!3BCRZ>W8Z,5@G1X$UE(E+2U" KVNIMB9
M*<M1'ZQFF$Z<D87W)EXG^55& V_#/OP/.7RU])C*'E)G7U"WUM;36OF7*Y46
MO5><GI>$CG9W5R\C$B_09: QURPX4&69#A(B-AL:B(A^+M3!$U)H34FY$T)V
M=F!*'#.IS#&TZO5Y+SRWI@K&.L>KMW[=K1ZXI2?1LB;BG7=GMO&BT>/''=%]
M1:<EO;Y/'Y.M9V\)O>/:[KN6#WL2S$!\:#8+)+7JJU6N2!4+65ZGT-K7XHUT
M2E4F#6XD2&MV=<VJP7YJ_61KL$XW,I'O072"JU[:#1LGEDX=ZYCH%'J%=CW9
MR*F>^KU)83HB-3-5S8+6*JJJ,2Y$.N-FH+D-VTG5YPC#MMHZ7GTYK7R[^N:W
MM-/HBL0T36=9/&\\SVM=?'$]U<-,>';U1:E8O^>TSZW+?;+V[_2KK3W/=E7G
MJ6URXLH5"LU36)BN#;Z3-/:GUKOJOSKD:B*U4O/P.M>U*Z1U3ZSZ9EMRCOZU
MC6/2%:*-)WM;H1OT"'*]6NUT/,>[^,Y3X,N0K<>]AZ/Z''[S1Z6NWHT^*/UQ
M1K^;I%Q#)]TUVKOW^^U&:>_VW_5W>B(?8?\ 9"\O/Y9\J'].+0__ !Q?"]H?
ME[8YKVY9\J&<QR.:JVVK[D1S5O15:^=<UR7I^"YJM70J*F!\<@[7[EZ;^3X/
MT./_ "NK^ZNJ_E.H_39/\SD0HGM<.DU35OE<MUOT^NL14F*E*5!JN5BLO6'4
M:?.,5+E_ 5JPT=<_-SVM<GT-8SW@;I5T5$:N466K+41J*VOV5L]/J]$1J?7=
M E)!][KOK.:YBJJN5%2_#AI*7(=+-T;X?DW[>BTEM_3IL6_Y^SN[N'I/Q+',
M337ZRNW=$:C+M^;M[3],;.S5DW]Z<RUTWJF6CL7D_M+!1S>NC2\.LT"<>U%^
MLD-TM/3<FQST6Y,^6B(U4:J(N*+R49(/>N,G$^Z%"MSDRME9ESE8R)-V?J%(
MM5*L<N#HT2%,K9V<AP4_#S(,.=CL1<QK8SDSG=&VX7(>#J^KCA&;?]ZQCF>Z
MV&^3'M[*Q;R?YZ2V#0]9G&\&W[]G+$?%SX\>3?VVFOE/S7AZ@^0?VSO1KRB/
MEY:B94Z%3ZE,N1D*DVJ29LE45B*E_5LA5Z!)08[FK@KI>/%A._"9$<VYR\F5
M'K,K/2\*;DYF#-RLPQ'P)F5C0YB6C,553/@S$%SX,5MZ*E\-[TPNOOO/'#BM
M16YJHCFK=>UR(YJ\6JBM7@J'TED Z9>5;)7--F\GMO[4655KF*^4I]4COI,=
M(:WPV3=%FUF:1-P6+BD&8DHD%5TPU1$NTCB?4YCYSH]7>L^%-12+Q/\ O,<5
MFOZ.S?>%]=^2)B-;HJVCQR::\UF/7Y++-HM/^]J]<&_FY1>=%SHJ^]+6^H[I
M:GY7;'4RV4DU6LBVALNL.SMH6MNN6-'I<7K*%4(B.^N])5:,VY%;"@9RHJ=I
M3H>>U%R)9<H<.%86VLD^N.AK$BV3K:?<.U4NB8O3[DSKT=.MAM5'18])CU&6
MAHYJ/CM=>U(PXUT,XCH(FV;3VMBCOS8O=<41Z;6KSI'H\I6F_@EG@/3KAG$=
MJZ?4UKEGNP9O<LN_HK6T[7GYNUW(@"U')M[]/:,Y-IJS;EP
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M(M,QRWB$P\&Z1:+B%.WI-1CS1'OJQ.V2GR\=MKT]'G5B)\)E_5@I>A4\A[0
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M"ID
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M]/M^QPO6WY\JZ/->>_GRTUYGQ[O(S,_[+\'#M4 QM??X;/0R$'+
M             #J>>]?_ (N<DWZ0JK^R%0.CD=XWWK_\7.2;](55_9"H'1R+
M2=5OP/A^<S_6W5+ZV_AK-\SI_JX  2(C,.R[[K%^/JV/Z+*A^TMGSK1'9=]U
MB_'U;']%E0_:6SYJ/3SX(UWS/]ZK<>K_ .&>'_/Q_5L[^8 *BKG@
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MZ;Z/BU/<;>3U%8WR:;),>4IZ;5VY9,>_+MU]7;K29B'[X"B*5-5;B
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M3LK?^16<_;"@'N=&/A+A_P"6Z7Z^CP.E?P7Q'\AU?U&1YF:Z5*%5TJ4+F*/
M                                  [X/NJGXG<H'Z2HO[,T8[1YU</=
M5/Q.Y0/TE1?V9HQVCRHW3WX8U_SL?5T7,ZN_@7A_S,_67  :@W0        /
MS7+)_>E:;\WJY^J9P_2C\URR?WI6F_-ZN?JF</K@]_3Y5?VP^.H^YW^1;^K+
MQ^=O%?,#;Q7S!>-04  $2H?W-,_Y-,_[B(>O-T8/Q;V!_,JR7[.TT\AFH?W-
M,_Y-,_[B(>O-T8/Q;V!_,JR7[.TTA/KG^Y:#YS4?U<2>>H_[IK_DX?VY'[J
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M)$>Y5<^(]ZJY[XCG*KGO>Y5<][U5SG*KG*KE52\ D6(V1F  R
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MXIOGKCM>NIQUB*VK2(W\O6-JTMSB(O6(I:TQ7LUG:;<^B*5+6:$+B)4R@
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M4E-T)P -2]5[//GL)%_/88H6OLNX<H7II^SGGB8VYL2O !ED
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M:/57_?V&OFVG_P"IQ5^/Z\M(^Z1\:/=(W\_L<B0+6+@7$8I9
M      !U//>O_P 7.2;](55_9"H'1R.\;[U_^+G)-^D*J_LA4#HY%I.JWX'P
M_.9_K;JE];?PUF^9T_U<  )$1F'9=]UB_'U;']%E0_:6SYUHCLN^ZQ?CZMC^
MBRH?M+9\U'IY\$:[YG^]5N/5_P##/#_GX_JV=_, %15SP
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MMI_!9LW^=EN?V@F3GL*<]+?A3B'Y7J/K++M]#/@CAOY%I_JJ@ ->;,
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MK8U.6N^ET=JWMO'++GY3CQ<^4Q&W;R1Z(K68VR0^OVLNN6^_NQYW&0 K$MB
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M?:/U?\OP?H\CR<NL3^4WO'6)_*;WGK&_V.SH_P#Y#,CW^K.QG]3#^QV='_\
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M,'XM[ _F59+]G::0GUS_ '+0?.:C^KB3SU'_ '37_)P_MR/W4 $!K#@
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M/:/^KCUI.K3_ !O^T[U*YB;_ /M.]3H3URZC^18?TM_\KT/M':;^7Y_T./\
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M[N>&HDK@AA@ZUY[C,J7W)O#,LS$P\.XO*(5.-?'VRP  Y
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M;3,S,[S,SO,S/?,S/.92]2L5B*UB(B(VB(B(B(CNB(CE$1Z(6YI< <7(
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M\[+<_M!,G/84YZ6_"G$/RO4?667;Z&?!'#?R+3_55  :\V8
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MS0G!/(K=UP?"6'\CQ_79UH.I7X+S_EV3ZC3K@ 10F
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M M)H,<8M)I\>&NW/LU\^^WC?).][SZ[VF5,WG[2F;S@7 \QZRB)<5
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MS,_N4+0FGG6JZU72J[5[LP!$2:@
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M.JE2BH5,1W  #(
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MG6B.R[[K%^/JV/Z+*A^TMGS4>GGP1KOF?[U6X]7_ ,,\/^?C^K9W\P 5%7/
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M7BT1,3$Q,1,3$Q,3$]TQ,<IB8\855FLQ,Q:)K,3,3$QM,3'*8F)YQ,>,3$3
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M9K:)BT3,3$\IB8Y3$QZ8GDN?2\6B+5F)K:(F)CG$Q,;Q,3XQ,<X  <7(
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M/L32QH,%MM1JZSY28GGCTV^UO9.:8G''XD9.[S9?F3.=O;O,A:UMQ<61A6"
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M1YGWL"?X5N3+A:;]G*@>F"S0G!/(K=UP?"6'\CQ_79UH.I7X+S_EV3ZC3K@
M10F                         /S7+)_>E:;\WJY^J9P_2C\URR?WI6F_-
MZN?JF</K@]_3Y5?VP^.H^YW^1;^K+Q^=O%?,#;Q7S!>-04  $2H?W-,_Y-,_
M[B(>O-T8/Q;V!_,JR7[.TT\AFH?W-,_Y-,_[B(>O-T8/Q;V!_,JR7[.TTA/K
MG^Y:#YS4?U<2>>H_[IK_ ).']N1^Z@ @-8<              #$K[EU=^CL
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M%#:F#60X4-K&-30UJ(;TP0]*\7>?J9RDDSOSGOE?.(B(B(Y1'*(]0 ##(
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MOOV<&>WWN');T]U+3W/+\E?P6)_B-X?@IHYT$LC2Z8-_FHG<B8DDN[50BO=
M #+D$6<6Z%%79!C+NPAN4E$2>8KH,9K457.@1VM:FESG0GM:U-N<Y42[6JH8
MEFO?'MAZC?16I+9')ID\DVL?#;+V(LI#1D2_K&I]PY)]S\Y$6^]ZKBE]UQ]"
M0ET?S5^)^99(H+H=DK*0WHK7LLI9=CVK^$Q[+.TYKV.WM<BM7>EVH_3V)H_F
MJ4?U5M\F2?3>\_GM,K\:6O9Q8Z^C'2/S5B$N'I7P[DT<#:PL+_YIK8>ONX7Z
MTWFSAZ^#?@?!]VSA:EYT&RA)HW)Y)\S6P]"<5-HS3V+Y(!.A)@G!390]/8GC
M<:Z%H3^:ILX>W<GFG.($Z$FCG63&+A_UOB0X>KL\U)T-,&\0)T/2O=X7DEGX
M*\5(L+T_V24S1V_$"0S\)W.PR7X.XH8(6E>=?/V&94^JO\X$,T/0G!/B96KC
MV)YF-B?#R0R,3%>*>0&9=14
M                                          Q1/*[Q,3N?(RQ/3S4Q
MKZ>8&#^*NY;_ !,,;0F[Y&1/XW#XJ61OP0,3TO1=Y$BZ$XDU_P /@0XFCM0"
M#$;B[O($1-'#X*;&)I7AZFOB)@G!$[[T U\34O.A%\S7Q4Q5-B+SXFPB>O\
MLD&,F/:OD!K'ZN'Q0U<77Q3S4VC]6R^[QO\ D:V.FG@OF!K(J>"^GJ:N+\>P
MVL73V^AJHOQ @1-*=OG<899;HL!?Y,Q!5.R(ST,\35Q7S(C5^LS_ *5G^TAB
M2'EU=*RGME,J>4F78KE9"M_;-&J^Y7*C[1U**N=<B(N,1;EN3"[3I/P<^L>G
MHB)ENRLW77?\(5I]&C_TC&V8'R<7;X9;?3:>WWV#%/Y\=94.XK7;5:F/1J,T
M?FR6C^P !WG0#%$7P,I9$T&)8GN>AC[#F??,=%W)@^(C46&VUDLF:BHG5REM
MK12\)5O5WUNKA-5[D6Y7YRHUMZ-3ER9J7>OFAPO>P/>J]&2QB*KE1M8MFC45
M55&M_=-4G9K4_BMSG.=<ES<YRKI557F@A^GDA3;I37;B?$(__NZKZ^\KP=$9
MWX5PW\@T?_3XVQET\T\C:P5__2-7+_%/(V4%?_TCP6PMI"T+=M^9L86A>*&N
MA:%YU*3X>E>#?@!M&:N*^:&PANNNW+X)AH[37LT=J^:$Z'I7G^,!L86GL0F0
M]#>[O(<+3V(3(6AO.T";#TKP^)E1+E;VKXF*'I7A\2]$5%3AY8<^($M-/8IU
M>/>HOQ,V#_21"_4%2.T.FGL4ZO'O47XF;!_I'A?J"I&W= _AC0?/?W+M,ZQ/
M@3B'S-?K*.B, "W2F0470I4HNA0.S?[K12)6>RO939*=EX$W)3F2J+*S<I-0
MF1Y::EIBTE/@S$O,P8C70XT"/">^%&A1&N9$AO<QS515/F[VVWLD)O(#:9;8
M6.DYB/DDM3/N;3GM2)'_ '&UF85\7]S$_&<YT1TA&1KXMG9V,M\6 R)3IAZS
M4K#B37U)[JC^.G*)^C%/VHIIW?,M.1NS>4"RU;L;:ZERU9L[:&1BT^J4Z::B
MPXT"*E[7PWHF?+S4M%:R9DIN"K)B3FX4&9@/9%A,<D#=(^E.7A?2#)DKO;!D
MPZ:NHQ1\>GDX\ZOA&2F\S2?'G6?-M*P71?HAAXOT:Q8K;4U&/-J;:;-^#OV_
M>VVYSCOM$7CGX7B)M6'C]M<M_//R[3.<E'M0_9N6DZ-V4"+0)U9BJ6/K3IF>
ML/:E\)4AU6F0XB=93YY[6-@PK04=L2%!JDNW-2,QT"HR[/HTRG5\:R*3;P_7
M8M3AQY\-XR8LM8M2T=TQZ_1,3RM68B:VB8F(F$$Z_A^;2YLFGSTMCRXK36];
M=\3'C$]TUF.=;1,Q:LQ,3,3$JE%0J#N.FRRDU%E8T&9EHT66F9>-"CR\Q B/
M@QX$Q!B-BP8\"-#<V)!CP8K&18,6&YKX45C7L<CFHJ>A3["[VO,++=9UN3ZW
ME1@P\K%F)!JI,3#V0W6YH4HQC/N[+HJ-:^MR*9K+0R<)%<]5AU>"U8,Q-,E/
M/1/[?)CE-K]BK146UEEJG,4:T-GZA+U.D5.4==&DYR6<KF/1J_4B0HC5?!F9
M>(CH,S+18TM'8^%&>U=4Z7=%L7%--.*VU,M-[8,VW/'?T3XSCOM$7KSWVBT1
MVJU;;T-Z6YN$:J,U-[X+[5U&#?EDIO[Z/",E-YFD\N>]9GLVL]A1CE7GGGPR
MG%)[*'VFU Z2%@H=03Z/2[>6?A2TE;BS3'I_Q6=>Q6P:S3&.7K(M!K*PWQI-
MZHKI.8;'IDPYT669&F.5AF@J;K]!ETN;)I\])IEQ6[-JS^J8GQK:-K5M'*U9
MB8G:5QN'<1PZO!CU&GO&3#EKVJ6CT=TQ,=\6K.];5GG6T3$QO"\ '4=T
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M2*5CQG;OM;TWO:9M>=N=IF0 '1>B
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MB%L^JGCTZSA=<5[;Y=';['MOWSCV[6"9]E)\G'S>_BR  CM)H
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MF5S<.*N.E,=*Q2E*UI2M8VK6E8B*UK'A$1$1$>$  /F^@
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M;V!_,JR7[.TTA/KG^Y:#YS4?U<2>>H_[IK_DX?VY'[J " UAP
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MCMUC^+RQ&V3'/CO6^\1OWUVM'*890412IX[W
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MG;Z>2&2'I7C\#&WT\D,D/2O'X 9@
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M#%NZ6+=TO0!]@;_!EL=_GBV?[33YS/M7GLYQ.%_V!B__ $,ECE__ &S;-/\
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M^BRH?M+9\U'IY\$:[YG^]5N/5_\ #/#_ )^/ZMG?S !45<\
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MX4XA^5ZCZRR[?0SX(X;^1:?ZJH #7FS
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M:QX+>=5_!8T?"<%IKMDU?[YR3X[7B(Q1OZ(Q168CPFUI\97  T)(@
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M7L5'L>U',>U45CVN2]KF/2]KVN145KFK<J*BHJHIG:Z\TIO:X
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M+5]"X,  #(
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MSTM^%.(?E>H^LLNWT,^".&_D6G^JJ  UYLP
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M?]ZR_%+DY_2,_P#9JI&W] OA?0_.6^JR-*ZQ?@3B'S5?K<;HG:^_X%2FOO\
M@5+<1W0IE3N  9<G,;[ G^%;DRX6F_9RH'I@LT)P3R/,^]@3_"MR9<+3?LY4
M#TP6:$X)Y%;NN#X2P_D>/Z[.M!U*_!>?\NR?4:=< "*$P
M         !^:Y9/[TK3?F]7/U3.'Z4?FN63^]*TWYO5S]4SA]<'OZ?*K^V'Q
MU'W._P BW]67C\[>*^8&WBOF"\:@H  (E0_N:9_R:9_W$0]>;HP?BWL#^95D
MOV=IIY#-0_N:9_R:9_W$0]>;HP?BWL#^95DOV=II"?7/]RT'SFH_JXD\]1_W
M37_)P_MR/W4 $!K#@            #A8]X$RI_N8Z+>41L.*Z#,VC^X-E)9[
M'(UV=6:S*+,,2]%O2+(RDW!>B8]7$>J;4\U)BI>MVC&[A?\ 8=\3WJJW422R
M.V#H#7W,K^45D>*R_P##AT*@5*<:[\)/JLCQH:+>UZ(Y[?P;\XZ'4/=HQ+,=
M4NF['"YOMSS:C+??QVK%,<?KI957KCU7;XO%/##I<5-O#>TWRS/T^4B/HAE
M!*"*0Q.A1'KF0F.B17_5A0V-5SXD1WU8<-C6XN>]ZHUC6HJN<J(EZK<93ZEZ
M#63K]UV6G)19M6=:RKY0[(R\:'_[26@UF5GIN&N*81)24CL5=*(Y51;[D/AJ
ML\8L63)/=CI;)/LI6;3^J'WTVGG-DQXH[\F2F..6_.]HK'+Z7J+]#K(Q R=Y
M*\GEAX#&L_<Q8Z@4B85B(B19^6ITO]TIE43!'350?,S3[L,^,ZX^E##"2Y+N
M-UR87(MR(G!$1+OD9BD>?-;)>^2T[VO:U[3Z;6F;3/TS*^>GP5Q8Z8J1M3'2
MM*QZ*TK%:Q]$1  #Y/L                                        '
MXKTB,A-G<IMB[26#M7*).T"U%*F:54(*?5BL9'9?!FY6)_ZF=D)AL&<D8Z8P
M9J!"?H147]J+',O^TYXLMJ6K>EIK>EHM6U9VFMJSO$Q/A,3&\2^>7%7)2U+U
MBU+UFEZVC>MJVC:U9B>^)B9B8]#R7.FST0+4Y"\H]?R>6I@JLQ3(ZQZ35&PW
M,E+14":>]:579%5^JZ#.P6YDS#8YSI.H0IR1C9L:6<T^4VK>>H#[57V8UF^D
ME89U+CQ(%'MQ063$W8BU+X:N20G(J-6/2ZHV$G73-!JJ0FPIR$W.?)1D@U*5
MAOF)=8,?S6,O.06UV3&U56L5;>BS5!M'1HZP9R1FF+FQ(><O43LC,(G4S]-G
M&)ULE/RSHDO,PESFN1R/8RU70CIECXG@BMYK75XJQ&?'W=KNB,V./&EO&(^Y
MV\V>4TM>H'3WH5EX3J9M2+7T6:TSI\G?V)GGY#)/ADK'O9GEDK':CG%JU_)P
M4;H*F]M"  !13"L%%2Y414OOS51%2]-"W*FE-6&DS@Q,#[;Z,_M)<N61]84.
MP>4>T5,ID-^?^Y^=F4K=G'WW9_\ R)663LE 6)<B/C23)2:5$1&QVW)=S]]'
M7WJZU,BD"4RI9.*77H;6,AQ:U8R>B46><Y')GQXM%JBSTB]<W_U4O/P<Y="M
M2Y#J4*V\LZM.>>5Q-;XKT1X=K=YSZ7%:\]^2L>3RSZYR8^S:W\Z9_P =FX1T
MQXGH=HTVLRUI'=BO;RN*/5&/)%ZU_FQ$_P!GI79 ?;_=&*W:0H,2W:V(J,6Y
M$IUOJ?,6>1M_\JL(Z<LZU+\&]96(<1^EL.Z]&\N%C<HE"M')PJA9ZLTJNR$=
MC(L&<H]1E*G*Q8;TO9$9'DXT:&YCM3LZ[P/'B2&A_?9.<J=I['3K*E9*T5<L
MQ/LB-BMFZ!5IZD1EB-5%:Z(LC'@,CJBHF$=D5JW)>U;DNCSB/4YI[;SI=5DQ
M3]YFK7+7V1:OD[5CVQ>4E<+Z[=33:NLTF+-'W^"UL-_;-;>5K,^R:1['L(-B
MHNOR^'CL,IYO/1Y]XGZ2EA5@0*K7Z1E&ID),Q96V]*;&GE:J_7<E>H\2F55\
M:["&^;C3D%BIG+ >F<UW/OT;/>D\E-H%@R>4BR=H<GLX_-8^I2#F6NLZCE5J
M*]\:4@2-:E6*N<Y71*1$@PFW*L=]SE2/N)]6G%=-O-<5=32/C:>W;G;YNT5R
M[^JM+>V4D\'ZU.#ZO:MLUM+>=O-U->Q7T3[K6;XHC?[^]9]3M'@^>\@G2HR=
MY4:<E5R>VSL[:Z3ZML6*M%J4O,S,JQ[G-9]-IZN94)!SW-7-9/2LNYUV"+I/
MW]C]6&&!HF;#?'::9*6I>L[6K>LUM$^B:S$3$^V$A8<],E8OCO7)2T;UO2T6
MK:/3%JS,3'LEE !\WU
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M01++"Y\.?(S)^$G:G:8(&OL\C,JW7<3$C.OIYEQ;<B\["J"O<PJ #+(
M
M        !(P/_"3AZ&-ZX<[%,CM*]G/@88NCM0Q'= PI=<WG5S]I9$7%O$R(
MNC<A@54OX(J]_KX[#(P/N\4\UY^5QAB+BG:95U8<W7>>'AH(SE2_G6N'?J C
M1-#N=AKXMWA=VX<]Y,B+??L54[4UW$%[L<;MNG'7?Y 0XNE=EW<:R.N'_5].
M=YL(BX.7GG$UL:Z^[>B=WIX 0HJXKN]%-7'75P\#8Q%P==K7L4UL7%>]>W0!
MKHJ^2^AJHJZ.=&/?P-E&W[$\<?L-;$71WKNPV@0(FO@G/KXG\S:JH0Y2FU&:
MB/2%#E:=4)E\1RHUL-LO(QXJO5SL$1N9?>OU4NQPO0_I8N&=VIVX>*GS'TS+
M8?N?R293ZVC\QU)R?6OGF*CLU>M@T*>=!:U4<U<^)%S&0T1S55[FHBHJH??3
M8IR9,>..^]Z4CVVM$1^U\-3FC'CR9)[J4O>?92LVG]CS#YZI.G9F/.OOZR<C
M19Q^==G9\W$?,OSLUK6J[.BKG*UK6JZ^YK4P,)%@-N1C?Y+6MU78)=AW$HN_
M6-HB([H4'FV\S/IF9Y@ .3 6.5$5%7!$7%=B)BJ]Q>19Q;H454TI!C*B)IO2
M&Y4NNQ71=<FF^Y,;C$]P]+OV9U#=3NCWD7E7(Y(B9.;,1XK79BJR+-R#)J(R
M]E[5:UT;-:J*JJU$OQO/N^'I3M7S/PSHY67^XF3ZPE(S4;]S;'V8D\U,U;EA
M462O:F8UC,+UT-:FG!%0_<H:8\$1?/24DXCF\IJ,^3[_ #9;_P#%>UO[5\^&
M8O)Z;3X_O,&&G_#CK7^QM(7\7C\#90<$_P"K\5-?"31P7GY&QA)JU87=Z'3=
MULH:X)Q^*&PAKI_G?$B,3\'CZDR&N/;?PPT@;)BW*B\Z\2?#30EV]>X@0DT8
M7?54V$-<5[O!.4 F,7!>?XO/VDV&J>"^2<_,AL1$3M7S3GQ)S$2_G:O/B!,9
MI7@7L2]R<#&Q/PEW7>!G3\)." 9E3\+^;\3J]>]2_B9L'^DB%^H:B=H55T\#
MJ]>]2?B9L'A_^$B%^H:D;=T#^&-!\]_<NTOK%^ ^(_,U^LHZ(P +=*9A1="E
M2BZ% [07NJ/XZ<HGZ,D_:BFG?/.AA[JC^.G*)^C)/VHIIWSRK?6E\+Y?F=/]
M7"V?5'\"XOGM1]8  CM)H88T)KVJUS4<UR*CFJB*CD5%14<BHJ*BHJHJ*ERH
MJHN"F8 =!'V]OL?%R6U:<RPY-Z7FY.*[/+$M-1I&&O5V(KD_&5?I$O+PVHDO
M96K3#_WC,1(%&J,19&Z#)3$BUG6<O/8GMO8RE6AI%2H5;D)6J4>L24S3:I39
MV$V/*3\A.P7R\U*3,%][8D&/!>Z&]JXW+>U6N1%3S9_;%^RKJ?1RMHDY18<W
M4,EEJ9J,^R57C7QHE)F;G3$:R=7CWN59Z1A(Y]-G(MRU:F0^ON^ERTZUEB>K
M?IQ]DTKH-7?]\TCW#):>>>E8]Y:9[\M(CO[[TC>?.K:;5FZT.@7V)>W$='3;
M2Y+;ZC'7NT^2T^_K$1RPY)GN[L=YVC:MJQ7AQ!:CD707$OH8"QV%RHERIBBI
M@J*F**BI<J*FE%145%2]%1<4O%QB1WR/8$^V"_X2J7*Y&LI-41<H="D4996M
M3L1C(EMJ%(PKEE(T5V;UUJ*-+L19BZ^-6*8SZ>C7S,I4'KV@6;=6G3JN/'2L
MM:NIT&J4ZMT2?FJ55Z1.2]1IE2D8SI:=D)Z3BMC2LU*QF?6AQH,5K7L=BF&:
MYKF.<U?2)]C5[5FG=(JQBT^N/E:=E2LI*R\&U=*A*V%"K$LN;!@6MHT!7*OT
M&?B(C*C*LO6E5)70'72L>2B1:Z]9'0?[&O;7Z2G[VO.^?'6.6#):??UB.[%>
M9YQW4O.T;5M6*V8ZK^GOV72O#]9?]]8Z[:?+:>>HQUCWEIGOS8XCE/?DI&\^
M=6TVYJP6M4N(B30     .IY[U_\ BYR3?I"JO[(5 Z.1WC?>O_Q<Y)OTA57]
MD*@='(M)U6_ ^'YS/];=4OK;^&LWS.G^K@ !(B,P[+ONL7X^K8_HLJ'[2V?.
MM$=EWW6+\?5L?T65#]I;/FH]//@C7?,_WJMQZO\ X9X?\_']6SOY@ J*N>
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M4X7PZL>&ATOYYP4F?US( #PVP
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M?\5L=?[D+$=1N./(\1OXSET]?HK3+/[;RO !"R>
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M?P6;-_G9;G]H)DY["G/2WX4XA^5ZCZRR[?0SX(X;^1:?ZJH #7FS
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MTN'28(VQX:12N_?:>^U[;=]KVF;VGQM,@ //>D
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MLQ M;D[M%*5VF.5D.<@MOEZI1YQS<Y:?6Z7&NFZ9/,5'(D*.SJX[6K&E(LQ
M5L5WU"CK^?D0SGP7Q7MCR4MCR4F:VI>LUM68[XFL[3$^U.6GU&/+2N3%>N3'
M>(M2]+1:EHGQK:-XF/8N !\GV
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MP[K^/KH,IQB.]@ !R
M                             "\H[0%+7K<G Q:/_/4,.M5VJ8(KM7'T
MT<?#$SH1U5<Y.=-Z_9MUF11VO<B>2D76[L3Y)S@2472NV_@1FHG>J^&.&[E
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M57_&^"\\=P$A5P7L\CJ]^]2X9&+!?I'@_J"I>IV@7:%V*OEL^/@=7[WJ=/\
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MUM-J4_3XN>C4=UDC-QI5^<C'/8CLZ"N<C'N8BX-<YJ(JSIU+Y/A&OKTMH_\
M]B)G]GYU?>O/%SX9?U:RO_33']OYFG !.B 0Q/3%.>;]1E,,3T^)B6)>F][!
MZJNF^B=D<B/S,Z'1JY+*D-<$;)VPM'*PT5+U7/6%"AN>BW+G+G7(BH<O!P*>
M[<VR95.BY9F4:Z]UG[26QHCTN:F:]E6^Z>;]5J*[ZE4:[.<KG?6NSKD1K>>L
MIMTHQ]CB6OK_ /W-3,>RV6]H_5,+O]$<T7X5PZT?R+2Q/MKAI6?UQ( #P6Q
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M^L/U&9/<>(T\8RZ>_P#QTRQ^:.Q^MLP$!"B>0
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MG\%FS?YV6Y_:"9.>PISTM^%.(?E>H^LLNWT,^".&_D6G^JJ  UYLP
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MI?L_-7;4ZNL>3B8YXM-OO7V6S3MDM^)&..4]J%6)<A< 16EX
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M;IIGV>6IO^IZA4);T1=W/.XR&& OU&WZ;DO3>B8F8IHO
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MM#.[+#7%>ST,FOM^'/V&!<%O[%^"]BDE-!QWYL2J #D
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M?TE+K?=5FOC/P731OO;!;+@OZII>;5COG^+O3Z/#;9D !H:0P
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MGL*<]+?A3B'Y7J/K++M]#/@CAOY%I_JJ@ ->;,
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MZ*9QSMJ-1VL6"8^+.WGY?1[G6?-_'FG*8W;]U==%8XIKXC)&^FTT5S:B/O\
MG[GB]F2T3VOQ*WVF)V<J= HLK39.4I\C+PI22D9:7DY.5EV)"@2LK*PF0)>6
M@0FW)#@P(,-D*$Q$N:QC4U*;LHC40J51F>^9[YG>97!B-N41M$<HB/   9
M                                 .J_[UE^*7)S^D9_[-5([4!U7_>L
MOQ2Y.?TC/_9JI&W] OA?0_.6^JR-*ZQ?@3B'S5?K<;HG:^_X%2FOO^!4MQ'=
M"F5.X !ER<QOL"?X5N3+A:;]G*@>F"S0G!/(\S[V!/\ "MR9<+3?LY4#TP6:
M$X)Y%;NN#X2P_D>/Z[.M!U*_!>?\NR?4:=< "*$P
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M=H]%J6FL_KA?/1ZJN?#BS4YTS8Z9:3^+DK%Z_JF  'P=D
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M^!@:MY=#P6[FZ[UU&+?_ ",Z<]I4M73W<\]A<98C_P _L  &0
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M[+ONL7X^K8_HLJ'[2V?-1Z>?!&N^9_O5;CU?_#/#_GX_JV=_, %15SP
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M3H+SM&>(SX8F?XS''9R5CTS;'M;V8I<\@+6Z$+B %C@
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MPYJY*4R4F+4O6MZ6CNM6T1-;1ZIB8F/4  ^;Z
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M21I7^UP_YK/]A"27BC_']J@5.X !ER8H_P" _P#F.\E/7NZ./XO;"?F99?\
M4<@>0C'_  '_ ,UWDIZ]W1Q_%[83\S;+_J.0(2ZY_N7#_EZC^KA3QU&_=>(_
M-Z;^MF?LX ($6(                                      ZK_O67XI
M<G/Z1G_LU4CM0'5?]ZR_%+DY_2,_]FJD;?T"^%]#\Y;ZK(TKK%^!.(?-5^MQ
MNB=K[_@5*:^_X%2W$=T*94[@ &7)S&^P)_A6Y,N%IOV<J!Z8+-"<$\CS/O8$
M_P *W)EPM-^SE0/3!9H3@GD5NZX/A+#^1X_KLZT'4K\%Y_R[)]1IUP (H3
M                       'YKED_O2M-^;U<_5,X?I1^:Y9/[TK3?F]7/U3
M.'UP>_I\JO[8?'4?<[_(M_5EX_.WBOF!MXKY@O&H*  ")4/[FF?\FF?]Q$/7
MFZ,'XM[ _F59+]G::>0S4/[FF?\ )IG_ '$0]>;HP?BWL#^95DOV=II"?7/]
MRT'SFH_JXD\]1_W37_)P_MR/W4 $!K#@            #\TRR9.I2V%D[3V3
MG\9*T]GJU9Z;2Y+_ *-6:;,TZ,J?XR0YA5:NE'(BI<J(J>0G:6RL[0JI4Z)4
MH2P*C1:C/T>H0'7HL&>I<W&D)R"J*B*BPIF6BPU14145N*(MZ'L8Q6*NB[=?
MMW\,%[#S-_;N]'E<GG26MVV%+K I5LWREO*5<S,AN;7X:_=9L._\+J:Y+5!T
M54P2)'NO529NISB45U&KTMIY9<=,U(_&Q6FMHCUS7)$SZJ;^"#>NWA?;T^CU
MD1]QR7P7F/O<T1:LSZJVQ3$>N_K</H*(MZ%2P2N(88B<]W-YF!B8W'>=]UEZ
M2C:SDYMIDOG)C.G;%5YE?I4&)$58BV?M2UW6LA-5<(,G6I&;3-:BM9]+1SE3
MK6H=J^&N!Y??L9^F$W(ME^L?7ZA,_1K,V@B/L7:QSHBM@0Z/:"+!@P)^/=>F
M92*O"IM2<Y&N>DO F84.[KW7^H#"BHK45%OOT7+>BIM1="IL76F.BXJ[UG<'
MG2\3OEB-L6KKY:L^'E(\S-7V]N(O/JR0MEU3\<C5\*IAF=\NBM."T>/D_?8;
M?)[$SCCUX[>AG !'23@
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M///>7&&$NF_G9X:C(B<[SC$^ N !R
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M8VOFBVHO_OI[5-_7Y*,<?0IWUE\5^RN,ZN8G>F":Z:G/>(C#&V3;_?3EGDJ
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MYT,/=4?QTY1/T9)^U%-.^>5;ZTOA?+\SI_JX6SZH_@7%\]J/K  $=I-
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MF%VN \:P\0TF'5X)WIEKO-=]YQWCE?';\:EMX]$QM:/-F)7  \I[
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M6Y,N%IOV<J!Z8+-"<$\BMW7!\)8?R/']=G6@ZE?@O/\ EV3ZC3K@ 10F
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M4Q,<XF.^%0 8<@
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MR1&W=M%YB-E]N'WFV#!:=][8<<SOW[S2LSOZP '5=L
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M\.<> AX.NVZ.[Q#*2N&/9SP)&HP+B7PW:ETW;/'A\3$L,J+L*EJJB:BXR
M
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M/=4?QTY1/T9)^U%-.^>5;ZTOA?+\SI_JX6SZH_@7%\]J/K  $=I-
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MF)F)A;C0:_#JL-,^GR5RX<E>U2])WB8_LF)Y6K.TUF)B8B8F%P .J[8
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MZS'6/+X-]I]$Y<43SMBM.WC,TF8K?OK:W[0"W/0N-,;R
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MIQ#\KU'UEEV^AGP1PW\BT_U50 &O-F
M        _/<K?]ZMI?S?K7ZMFC]"/SW*W_>K:7\WZU^K9H^N#W]/E5_;#Y9_
M>7^3;]DO'HE?[7#_ )K/]A"21I7^UP_YK/\ 80DEXH_Q_:H%3N  9<F*/^ _
M^:[R4]>[HX_B]L)^9ME_U'('D(Q_P'_S7>2GKW=''\7MA/S-LO\ J.0(2ZY_
MN7#_ )>H_JX4\=1OW7B/S>F_K9G[. "!%B
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M,'XM[ _F59+]G::0GUS_ '+0?.:C^KB3SU'_ '37_)P_MR/W4 $!K#@
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M.QL2#'@1H3G0XT"+#<V)"BPW.9$8Y',<YJHILD5%T$!+&Q*H
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M/*8GN,66MZUO2U;TM$6K:LQ:MJS&\6K,;Q,3'.)CE,+@ <',
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M #D
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MN^ZQ?CZMC^BRH?M+9\U'IY\$:[YG^]5N/5_\,\/^?C^K9W\P 5%7/
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M!DOBRXY[5,E)VM6?V3$QRFL[UM$S%HF)F'J0^SY]J=DMZ1-)2+96I-I5JI6
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M!/W;3^"S9O\ .RW/[03)SV%.>EOPIQ#\KU'UEEV^AGP1PW\BT_U50 &O-F
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M0/3!9H3@GD5NZX/A+#^1X_KLZT'4K\%Y_P NR?4:=< "*$P
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M-ZK@NF[88(;[TYYYXF3'4)C<9T*EC%O0JBH8K/YV%P .3(
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M .I!]\']$[\IZ_T3M?\ U(>:KCM48[5'VG^&_AM9^DP_Z<^W5Q7\!H/T>?\
MU#TJOO@_HG?E/7^B=K_ZD'WP?T3ORGK_ $3M?_4AYJN.U1CM4?:?X;^&UGZ3
M#_IS[=7%?P&@_1Y_]0]*K[X/Z)WY3U_HG:_^I!]\']$[\IZ_T3M?_4AYJN.U
M1CM4?:?X;^&UGZ3#_IS[=7%?P&@_1Y_]0]*K[X/Z)WY3U_HG:_\ J0??!_1.
M_*>O]$[7_P!2'FJX[5&.U1]I_AOX;6?I,/\ IS[=7%?P&@_1Y_\ 4/2J^^#^
MB=^4]?Z)VO\ ZD'WP?T3ORGK_1.U_P#4AYJN.U1CM4?:?X;^&UGZ3#_IS[=7
M%?P&@_1Y_P#4/2J^^#^B=^4]?Z)VO_J0??!_1._*>O\ 1.U_]2'FJX[5&.U1
M]I_AOX;6?I,/^G/MU<5_ :#]'G_U#TJOO@_HG?E/7^B=K_ZD'WP=T3EN1,IZ
MWJJ(G_S3M?I7#71+CS5<=JE\._.;BOX2>8^T_P -_#:S])A_TY]NKBOX#0?H
M\_\ J'KY9#\MMF\HUDZ%;>R%0^ZMFK2225"CU!9::DUFI18L2#UBRLY"@34'
M]\A1&YD>##?]6_-N5%/UI#BT]B@G_P!"MD1W6.9^LZ@<IA7WB>FKAU.HPUF9
MKBSY<59MMVIKCR6K&\Q$1,[1SVB(W\(63X5JK9]+ILUXB+9L&'+:*[Q6+9,=
M;S$;S,[1,\MYF=O$ !T7?              _/<K?]ZMI?S?K7ZMFC]"/SW*W
M_>K:7\WZU^K9H^N#W]/E5_;#Y9_>7^3;]DO'HE?[7#_FL_V$))&E?[7#_FL_
MV$))>*/\?VJ!4[@ &7)BC_@/_FN\E/7NZ./XO;"?F;9?]1R!Y",?\!_\UWDI
MZ]W1Q_%[83\S;+_J.0(2ZY_N7#_EZC^KA3QU&_=>(_-Z;^MF?LX ($6(
M                                  ZK_O67XI<G/Z1G_LU4CM0'5?\
M>LOQ2Y.?TC/_ &:J1M_0+X7T/SEOJLC2NL7X$XA\U7ZW&Z)VOO\ @5*:^_X%
M2W$=T*94[@ &7)S&^P)_A6Y,N%IOV<J!Z8+-"<$\CS/O8$_PK<F7"TW[.5 ]
M,%FA.">16[K@^$L/Y'C^NSK0=2OP7G_+LGU&G7  BA,
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M.:HG2#H[JN&9YT^JQS6><TR1SQY:;[=O';EO'IB8BU9Y6K6>2X%+RI[;PP
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M1'N>'>.7F1,S?;OR6M&\Q6LJHEQ4 T1(8
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MWIY=U_AB!N83O#%,=*:OGM)D)V'#OP\]G U,)^K<MWQ3@3V.T+J6Y5O[O+U
MVK'+RNK6G9J4F,=W*OV]Z=QK(;KKTT\X7]UUY,AKH3NYW78=P&RAJF*+V)NY
M4D,<NCNYW*06+WIAW_!?,DM=>B;KN53G:!*ONQ[TYU[#.BWIAIN2_>1FNO[%
M\^<%,D-;ENU:M6GGL S?XR)I\%1<>>PDHY%T$9=>M%P5/CSYAKLU=J+KW>FX
M,I.*:-!G147GTW\XF%%O0([-YV\XF)CT=["0A4M1<"J*(EA4 &60
M                                          "BJ AB9V8D7 CN6]5V
M>95SL[#5Z:N>!30@B/2R*J(15Q5=B+IU<ZO(N<Y56Z[MW+RA8B8;DW8KQU8?
M:9%U^WL3G7SM([EO5=B>.*\H5>^_#@O/QUF-RW(NQ-'KQV 6N=CO\DT>'BNX
MCO5+L-/CL7N+W.NQ7CMN3#!.<2,];K]^%WPY] +'[-R7]_Q^!!>_?V;-_H9H
MBZ4OTZ="7:/L\2$]4YU</._1?@!B>[7HNP7Y\$\2&]UW'PN]43$R/6_L1%[M
M"=NL@18F_P"Q-*]N/PPO PQ':;L=5_9BJ=A!B.U[+KKDUZ-/'OQ,SWZ[M*>&
M[PXD"*_1N^U>Y-'J!&CNTHO.&*\$V:4U&OB.O\.[7W_-3/%???O1-.S;Q\S7
MQ'W8[<$3P^:_("+&?X:-ZKI5-?*$&(Z[#Q\^W5AY&9[\>&"X78[>SYD&([G=
MBGEWW@87NUZM"<-NZ_#P. _V_O2__<'DH982E3:0K1Y3XD>F16L=^_REDI%8
M42O32(F+$J$5TI1H;OXS)B9:B*Q7JWG>JE4@2<O'FIJ/#E924@1IF:F8[T9
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MYUG:8[IA!&OX=GTN2<6IPY,&2O?3)6:3MZ8W[XGPM&\3'.)9@6M=>7'==,
M              !8Y]WV7EKHJ)?>J(B:UP\=7.S'&[&Z_.3:6N<ERXI=M5<,
M5N1.U;D1-:JB)>JH<D_0J]DMEMRZQI:8LI9:-2[,1G,6);:U#(]&LTR ]S46
M-(QHD%TY7+D=G(RBRLZQUSF]<U4<B=T+V?7L ,DF1I9&T%I&-RF6]E\V,RLU
MZ3A,H-&FM.=9^S3G3$M#BPEPAU*JQ*C4%<BQ9=TBU_T:'I72+IYH>'Q:MLD9
ML\<HT^&8M;?_ &EO>XH],6GM[3O6ENYO/1GJ^XCQ.:VIBG!II[]3GB:TF/\
M9U]_E\=IK'8WC:UZO@7W9/HW9<;&R]J;06CI;[/Y)[82$K.4RF5[Z1*5NI6@
ME5A0Y.T%&I+H:192EQZ8^+*3L[/I+)4V0J<^1A1X4LL<[<IA8VY?FJKXXKQ[
M-1F*S=(.-6XAJ\NJOCQXK9-O,QQ.T16(K7>9YVMM$=JT[=J8WVB.46KZ-\"I
MPW1XM'3+DRUQ;^?DF-YFTS:W9B.5*=J9FM(W[._?,[S( 'C/=
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M\7MA/S-LO^HY A+KG^Y</^7J/ZN%/'4;]UXC\WIOZV9^S@ @18@
M                            #JO^]9?BER<_I&?^S52.U =5_P!ZR_%+
MDY_2,_\ 9JI&W] OA?0_.6^JR-*ZQ?@3B'S5?K<;HG:^_P"!4IK[_@5+<1W0
MIE3N  9<G,;[ G^%;DRX6F_9RH'I@LT)P3R/,^]@3_"MR9<+3?LY4#TP6:$X
M)Y%;NN#X2P_D>/Z[.M!U*_!>?\NR?4:=< "*$P
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MTBN^O%CL60JC_K(VIPU>]731T8ZUYKV<7$JS:(Y1JL=8[7H]UQQW^N^.-_\
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M_P!C,BZBXM1;TT]Q5!$L*@ RR
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M,4TKDSX^Q2<DS%(GM5GSIK6TQRCPK//\[R8[UV>(O79XGI+?>[/1,_)W5/\
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M+T?S<,X?CTF>V.V2N3):9Q6M:FU[;QM-J4G?T^;  #5&X
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M&0X3&0X<-B,APX;&L9#8U$1K(;&(C6,1J(B-8B(ER7)<2VI<7 TUO
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M8G'.29[7;Q8]HGM1MMOX]S?@ C)*P
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M-_ ZS]%A_P!0?:4XM_*-#^DS_P"F>:]4%7Z/,X?_ $M,:_\ ]1$/7GZ+Z_\
M-O8#\R;)?L[33BVB>[K=$MS7,=DZJBM>US')_P (64+%KVJUR?WRZT54P.9Z
MR5EY*ATNG4:FPG0*?2I"2ILC!=%BQW0I.0E84G*PG1H[XD:*L.!!AL6)%>^)
M$5N?$>Y[G*L=]8'3/2\5IIJZ>F>LX;99MY:E*Q,7BD1V>QDR;SYL[[[>'>DW
MJXZ#ZOA%]5;4Y-/>,U<<4\C;);;L3;?M=O%CV]]&VV[^A !&25@
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M1O/C,RF3@O1W1</IY/2:>F&)V[5HC?)?;[_);>]O5$SM'A$*(5 /'>T
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MSP)"K<@%6)>M^JY43X\ZS-V["R$G/'%?ARIE.,3O/L  '(
M                  "BH5 %K6HA<  +5:FXN %$*@
M               45+RF:7 "S,3G[1F)N+P!2Y-A4 "W,38G*7%,SGE2\ 6Y
MB8C,3GE2X                                         6YJ;$*9B;N
M>TO %B,3=SVE4:FDN %JM12F8FQ.XO %N:F&X9I<
M
M
M
M                    M5MXS>>5+@!:C434A1&(7@ 45+RH LS$W<]HS$V)
MW%X MS4+@                               6JWGLN+@!;F)N&:FPN %
M%0(EQ4 45"F:A< *7)L*(TN
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M;+E7R3Q*IH3@7PD33OYY[3$SL,JE0!6.0  R
M
M
M
M
M
M
M
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M <@
M
M
M
M
M
M
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M#7Z+ZB6&9J8)PW%Q14O*F(  &0
M
M
M
M
M
M
M
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MB15[=6[>N\I$BJJX+NX;N<4TD1[_ )]WCY 7.=COUW]Z=VI.\AO=ANU\^:[
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M3(:</LV</%0+X;-J:5^?AIXDYFV[@G.W5PQ,3&;.U;NWO7636:;]2?9Z7:U
MO:F%VU?AW[K]NXEHW&Y.W<G.CF_$QNM=U^Q.!)8FG"]5P3X)W8KL N:MR7;/
M7#G3MN,T%-?.*\]^!C1MZW;+K]^CXWIP).G#M7GFX"E^O6N";DV]IE@MN3NY
MYVF-F*[K^W#5YX_&XD@%U)M,S$N0QPVXW\W:N>S0950Q_P"?_!*J*5 ,@
M
M
M
M
M
M
M
M                                                      %$*EJH
M8D1UP7=H[>=&S1I"MO,\1+T,"+X"LB*B8W+NN7AH7Y:RMUZ+?IYU>1?%AX7[
M^?4LOU[-/JFOL,LHJ)IVZ4WIL^.PQQ$[E3'U^!*B-T+L[\<>!AU:-/G\]H80
MXC+NU<?7R381'MU:E]=':FC5W(;%6W8*G#X\ZT(SFZM^'8!JW,^5UW?W8*A#
M>V[#'7X:.W7P-J]JKJQ1$[N?F0HC><=V%VU/(#5Q&]J[]FOOT;E[#7O9AAV>
MB[%-U$9CA=?\--W!2#$9@NQ5\>&B[E -0]B:-2IW<[-*&OBL3X\]F"ZK])N8
MC--Z<>.WXD*(V]+MG<J<;N\#1Q68K?L^Q>&TA/;HW?9]GJ;J+#Q7RU<.'*&O
M>S1QPW;47X> &DB0[E78OASK-3/R$*/"B2\Q"A1X$>%$@QH$:&V+!C08K'0X
MT&-">BLBP8T)[H46$]%9$A.>U[5:KD7^FB0]/''UYTFLB0[L%WJE^N_R&XZ%
MGMD_97Q\C->B6YL5)18F2ZT4]<V!":Z+^XNM3;G/^XDRY<YR4>;<CGT&<>J]
M6B/IDRJ1H,"),<&;5VGJQ91LG5%M70ZK9JT=-E:Q0JY(QZ;5*;.LSY>=DIEJ
MMBP7W*CX;K[HD&/"5D>7CLAS$![(T)CT\^+VH_LU*YT?K67RR3=4R=V@F8SK
M)VAB-17PG_6CQ+.5E[/JLK%/A+^]1U2&RK2</Z=!:D1DS!A6.ZN^G7V72NBU
M=_WUCKMBR6G^$4K'=,SWYJ1'G>-Z^?SF+RK#UF]7\Z*]N(:.G[TR6WS8J]VF
MR6GOB/#!>9\W;ECM/8Y5FD.+T%C7%Y+2'0  %,3FHB*O/;SMVF4&)@<E_LVO
M:<VLZ/UH%;#28K]@:M':ZT=D'S*L8KW9K%K-#?$SH5/KL"&B7NN;+5.&ULK/
M8]5,0>_AD"Z0-D\IMEJ;;*Q-9EZW0:HQ>JF(-\./+3,-&_2J=495]T:0J4D]
M>KFI.,U'L=FQ(:Q)>)!C1/+<>W1=SW'W#T$NG];C(':=*W9F/].HT^^##M)9
M2=BQ4I%>E(:W7O1MZR53EVJJR%5EFI'@N1(49(\J^) 6,>G'0#'Q")U&FBN/
M6Q'/NBFHB(Y5OW17)$1M3)X\JWWKV;4E7H!UCY.&S72ZN;9=!,[5GG;)I9F>
M=J<YFV*>^^+G,3O;'SWI?TKF/TW=N/#Q\R4Q]]R:;^>5TH?&_0WZ:MALN%E8
M5J+%3ZO6$D.#7*%.+#96[.5"(V]9&JRK'*B(Y4592H0,Z1J$-.LEHJN2)"A_
M7S')J[OAX>A6W4Z7)AR7Q9:6QY,=IK>EXF+5F/"8G]7A,;3$S$K1Z358\^.F
M;#>N7%DK%J9*3%JVK/=,3'YO3$[Q/.);-D3N\N/KW[2>R-?=?K[.?(TK(GSY
MY35N)+'?-/AN^R[2?!V&\9%7;AX+?IOW[-!-AQ-RWIWIVFAA1KL+L-B^7/'8
M3H;]G##5SL WD.-\.'R)3(GEH^)HFQ?MX[>>XFMB]FG7Z<W: -PR)H3P]%\N
MTDLB_##0N_B:ED5%NYNV\.S DM?MQV+K W#8FC%..A>>5)"/[>?'P4T[8GVI
MI[MOF2&1?/2FB[>G.X#;-B;^=:7Z4U&=L3CIQY]#5M>F&';?AV\_ SMB*F_A
MY;-(&U;$NT+HT[/&[CPQP,J1/3#1]GP-8D1-6_#>NK=S>9$B>>GASKT@;9(B
M[EYYT]I<U_8O/>AKT>G;W>7CL,B1='V+Z ;+K%W<\ZR]'IPYYN^1KTB)P\N=
MQD2(O%.>SG4!L$==H7XE<]>/!/B0L].'/F7H_ASO3$"7GIO[OBF!>C[]:=V/
MVD5'KL\?4NZQ.4 E<\Z2F&R[A=]NQ2+GIRJI\"^_>OCZ 24PT*[N*HY?Y7>G
M./R(UZ\H51R[O+RY[P).>O\ *12N<[=WIZ$;.79XJ5S_ /%\@)&<[=WIZ%,]
M=J)XF#/_ ,7R*9R[/%?@!G5R_P I.PI?AI=W&'.7=WJ4O7=W 94NWKVIY%>[
MO^!'5=Z\]Q:KD^U?M]>P"0KD36B<.5VEJO3CSM7G48.L39X%%B;$Y\_0#,K]
MB7<<?+[>PIG;_3G[",K[M?A<6=8G'G;SB!(ST31X8\\J6*]>'/=SL,#HFZ[G
MG3Y7F%7IO7R].'8!)>_:M_.SRW>./K%W)QYN[B.Z)L3GASX$=8F_'L7;LT8>
M2@2G/QVKV?8AA>_?AN7F\C+$34M^_9QU(8WQ$Y7!=F.GFX#.K[\-6].[PVZ3
M!$>FW5MVZK_AW&!7]G.S?O\ 0P.BIQ\N=:@9WQ%5-.&_9SX=Q'=$3;VKS\C
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MQR8  99    *7@5         +;P+@4O*@                 "BJ!4%$4J
M!15"*!4                   "W.YP N!;G<X#.YP N O**H%04O%X%0
M           HJ@5!2_G J                    %%47@5
M            **H%0412H                 %%47@5!;G<X%;P*@I>4S@+
M@6W\\^6G<510*@             **I4  450*@HBE0         !2\"H*(O.
M!4  6YR<W 7                              **MP10*@%%4"H%X
M        "BJ$4"H**MW*!% J           !2\"H   %%4"H*(I4
M       %+P*@MSN;T]2X "EXO J"W.YYYV%44"H
M
M
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M17JKGQ8K(36M<KHK42]>3;(WTN,EV4)B.L/E"L;:I^;GOEJ):.ES\[!1<?\
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M\2RQYL":5["<>K7HKH-=H<F75:>N7)759*1:;9(F*1BP6BNU;UCE-K3W;\T
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M%8M[8LO,07,C08C5Q;$A/8]JXHY#6.)=4.@R1,Z;+GT]O")F,V/_ (;=F_\
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M\5
M
M                                                     M52XHJ
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M/HUV1RL62J=B[:TQE2HU28BHJ*D.=IT[#1WT2K4F;S7/DJG)/=GRTS#P5%?
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M8B7=O/.%Y*0 7PVZUOQN^SX[M18U+UW<Z]W.!(4XSZ/SBE_-VPN*(A4Y0Q
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M&+_L*>M7T%/Q*Y(_T:6'_9NGD+]<OW#1?.Y?ZD)TZC_X1K_F</\ 7L^K0 0
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MS]'F*E!DYF-"2/"EYB) :J0HL2"J16,=^%#5')@I^R_V-/I"_D6RE?T5GO\
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MM'143U\SO5^]=_BGR8_I)C?LI6CHJ)Z^9:/JM^",/SF?ZVRI76W\-Y_FM/\
M555+':4+RQVE"1)[I1G/^'[7I'^[I_P3K ?YYRA?M]:$YQ#@[]W3_@G6 _SS
ME"_;ZT)SB%-NE/PGQ#\MU7UUUX.B7P7P[\BTOU-  '@MA      XDO;K?P4,
MLG^8J9^T='.6TXDO;K?P4,LG^8J9^T='/8Z/?"&A_+--]=1XG27X-XA^1:OZ
MC(\QQ=+OYR^8"Z7?SE\P7/CNA1I1?3S.Z?[I=_Z!RW_G!87]36A.E@OIYG=/
M]TN_] Y;_P X+"_J:T)H'6=\#:GY6#_J,21.JKX<T?R=3_TN9W @ 576\
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M"?#B2\S*2Z)!D'PWL<^HS,G!O1L1[F_&2O7===CL1+L;UU;U7!$0] 7W<'H
M?\'.3&)E2M%))"M?E0@2\U3V1X>;,TFPT!RQ:-+W.1%A1:[&5U=F67WK*OI4
M*(C8L&,PU'IMTBKP[0Y,L3'EK^Y8*SM.^2\3':F/&N.N]YWC:=HK/OHWW'H)
MT;MQ3B&+#,3Y#%[MJ+1RVQTGWL3'=;);:E9CG&\V^++L<T.DLDI.4E&19F,R
M4EH$JR-.3$6;FXK)>$R"V+-34=7QYF9B-8CX\Q%>Z+&BJ^+$<Y[U4W!1"I4:
M97.B-N4  #(
M
M
M *7 J6JO<8F-V)1\W-PU:O3T*JB+J0S.;>84V;.>PQ6?SLHF;FZ="Z]?/K>5
M78O9L5+^?L,\1MY'3^2NG5NX<-7Q.3+ YEU]^A?#>6.9I39]OCK^PE77Z>'/
M.PCZ+D5=%]R^'-^@,(RMOPYQUI\/2\C/;?JQT_#[=Y/<W&_0J8<\_&[ YMZ7
M[^[;\P-=$AWKHQ1-"\]RD5[4TIBN&'9YFS5M]ZZTU</7RN(CV87\$5.=GCW
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MZ?[I=_Z!RW_G!87]36A- ZSO@;4_*P?]1B2)U5?#FC^3J?\ I<SN!  JNMX
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M)_'5'MMA:.5CHZJ0;U1SK,T5%@S=:15:^&V?<^4I+8C7(DY'>QT!>X%T4/8
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MV'+CI><V3-EF]\TUBMK4KRQ4VB9Y4KO,\^=[6GNVB+@ :DW0
M
M
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M=.OQ?Y7_ ,^*#^S, [9I4CI_\,:[Y>/ZG&N3U<? G#_F[_790 &G-W
M       '\3E)_O>KG^9ZI^KYD\=N0_N>6_R:7_W,,]B3*3_>]7/\SU3]7S)X
M[<A_<\M_DTO_ +F&3OU+^]XA[=-^S.K[UY=_#?9JOVX$H $XH!=B3W8;^$I.
M_HRM3^M;-GH6'GG^[#Q$3I*3JJJ)_P V5J=.ZJ6;X<]QZ%38[53\)O>A6+K7
M^%I_)L/[<BU74Y\#_P#^7G_9C9@8^N9_*;_VD'7,_E-_[2$:)69 8^N9_*;_
M -I!US/Y3?\ M(!D!CZYG\IO_:0=<S^4W_M(!D!8D1JX(YJKL14+P
M !:[0O;Y%Q8], .AC[T-THWVARI68R6R4RKJ;8"BI6*K"8]%AOM+:AK7L9%1
MBXQ)"ARTHC6Q$582S[W,5O7/OZP!]1=.++A$RD98\I=N'QNOA6BMI79N0?J^
MY$O.OI]$AIN@4:2D(5Z7(JL541+SY=+D]%^&1H^'Z73Q&TTQ5F_SMX[>6?\
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M?TWM9=CHAT=Q\+T&'35B/*=GMY[1WWSWB)O,SXQ'*E?Q*U\=YFH -=;.
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MU-:Y]1;;SNU>-Z8Y]6*DQ7;N[?;M'OAJ%0#2V^        *7%0
M
M
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MKEOU)HY\R4A1$1"NE435K] 3(B7Z-%_*<\"1=J+6HB;"ZXX]_L841-9< <@
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MG_EHXN@=?_TYP_\ D.D_HV'_ ".U_P"I^)?R_5_TC+_F<HO]FJZ5/Y;;6?\
MV'93_P M#^S5=*G\MMK/_L.RG_EHXN@/_3G#_P"0Z3^C8?\ (?\ J?B7\OU?
M](R_YG*+_9JNE3^6VUG_ -AV4_\ +0_LU72I_+;:S_[#LI_Y:.+H#_TYP_\
MD.D_HV'_ "'_ *GXE_+]7_2,O^9VQ?88^TKR[Y3.D)1K)V\RFU^T]G9BREL9
MZ/2:A+T"'+1)NGR<G$DH[G2%%DIE'R[XKW,1LPC%5?KM>F!WBSSD/=O/X4M
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M[:>A6GKEXOPZEHWK]E8K3'I\G/E.?JWKSCQ[GH",3 O*-2[G<5*>+L
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M_P"M.+__ '+6?TC)_F<YGWQGTK?\,K-_T%H7H/OC/I6_X96;_H+0O0X,P/\
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MUH2/^L[X&U/RL'_48DB=57PYH_DZG_I<SN!  JNMX
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MW<B$XQ0?P4X)Y&4I/NOA
M
M
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MS$XXGNR2XPD4J86Q4NPQTIVII3BFMNE%P6XR(Z\WB):'NN !D
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M_P#5AI_VVN%^C5?H:_\ >;I]IOC'IT?Z>_\ V7G@YW-Z>HSD/0^^]E>C)_\
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MRC'@S7F?DXK3_8['!]/.76:3%$;SDU.#''\_+6O]KU(V_%?-2XM;H+BE*]X
M            XD?;L?P3LLG^9:)^UM /,=V\5\STXO;L?P3LLG^9:)^UM /,
M=V\5\RQG4]\'ZC\MM]1A5BZ[/A/3?D-/^HU(47T\RI1?3S)<0X[PGNG7XO\
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M3M6-5BBT\MHB]NQ,SOW1':WWY/3U9H[O)"XM9HWZ%+BG2[8
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M_P X+"_J:T)H'6=\#:GY6#_J,21.JKX<T?R=3_TN9W @ 576\
M               !Q1>W%_@HY:OS8EOUY2CS#G_A._G*>GC[<7^"CEJ_-B6_
M7E*/,.?^$[^<I8OJ=_@&I_*[?4X%9NNWX0TGY''U^9:6/Y[T+RQ_/>A+D]TH
M7GNEW;O=-/[SLL?YU66_4M2.W*=1KW33^\[+'^=5EOU+4CMRE2^L+X8UORL7
MU&)<7JQ^ N'_ ",W_4Y@ &F-\        <)GO#_\$K*5_E^3_P#]XEECS8$T
MKV'I/^\/_P $K*5_E^3_ /\ >)98\V!-*]A9'J?^#<WY9E^ITZK?77\+8/R#
M%]?J5P )71&]!KW7[^#A._I'M3_N*6=C8ZY/NOW\'"=_2/:G_<4L[&Q3[II\
M*Z_\HNNIT%^!^'?DN/\ 8Q16WX8*F**B[%TX:%14THMZ7:3HC^WL]C6^P,[5
M,MF2^E(EAJC,.F[;6<D(5S+'U*<CJZ+79"79>D*S%0F8K?I4O!8V#0IR)G-:
MRFS#?HG>]-16:-*U"5F9&>EH$Y)3D"-*S<I-061Y:9EIB&Z#'EYB#%1T.- C
M0GOA183T5L1CG-<BHI\NC/23/PS4USXO.I.U<V*9VKEQ[]T^BT=]+[3-;>$U
MFU9^W2OHM@XMI;:?-YMXWM@S1&]L.3;E:.[>MN[)3>(M7QBT5M7QP6K=IYYO
M,B*<^OMN?8_3F0BT$2W-B)*/,Y([0S^; 8SK(S[#U>;>YS+/SKG.B174B86]
M:!48KES;W4J;>DQ!E8DYP#H]"V/!^+X-;I\>HP6BV/)'+PM6T>^I>-YVO6>5
MHW]<3-9B9IQQG@^?0:G)I=33L9,<[?BWK\7)2=H[5+1SK.T>B8B8F%(B?#XG
M+)[)3VHU>Z-UMDB3'TNJY.;1S$O"MG9R&Y7N8UO[S"M'1H;KVPZW3(;E5T)B
M-2KR+5I\9R1&R<67XH#$]O///@?;B7#L.KP9-/GI%\62O9M6?U3$]\6K.UJV
MCG68B8[GQX;Q+-H\^+4Z>\X\V&W:I:/S3%H^-6T;UM6>5JS,3R>PCDJRI6?M
MI9RC6KLM592MV>M!(0*G2*K)1%?+3LE,L1T.*Q51'PWHN=#CR\5K)B5F&19:
M8APX\*)#;\Y>T77_ )ALL'Z.+7?J::.C+[$SVO,WD#M$VQEM)N:FLD=I)_/G
M?PYB)8JKS*M8MHZ? :U\6)3IES8;+04^#BL%OW4E842;@1(4SW@^GW7)*I='
MK*O4*=-RT_(3N2^U$W)3LE'AS4I-RDQ0H\67F969@O?!F)>/">V+!C0GNAQ(
M;FO:Y45%6KW&NBV;A7$L&.V]\-\^.VGS;<KTC)7S;;<HR4WB+U]<6CS;0MGP
M+I?AXOPO4Y:;4SX]/EKJ,&_/'?R5_.KXSCOM,TMZIK/G5EY24#^UP_YC/]E#
M*8H']KA_]&S_ &4,I;!3\.X?[I;_ ';ER_Z*P/\ MVG.G@=P_P!TM_NW+E_T
M5@?]NTYHW63\"ZW_ ''_ %.%OW5?\.Z#VZC_ *3.[H( *H+A   &GK,%8DK-
M0TP5\O'8BW7XOA/:F]<5T)BNK4;@CO:B?67"Y6JJWKJ7'PWB)8F'CLVRI[I.
ML5B3B+?$DZM5)1_U7,57RT_,P'KF/N<V]T-5S77.;^"Y$<BG\XBGU5T\LG<6
MR>6S*S9V*S,=2\H=K6-:J7709RLS53E41+U^K]%GH.:J+BS-=C?>?*K=!=[1
M9XR8<62.<7QTO$^$Q:L6C]JA.LP3BS9<4Q,3CR7I._IK:8_L5.1WV/U?@TSI
M/Y$YB/=F1K<R%.;>Z[]^JD":ITOC<N/734-$;=]9;FWMO13CB/TO(?E)BV-M
MM9"U\!V9%LO:>A5]KT<K<UM*JDM-QESFW.2Z#!BXMQ3 ^7%,$Y=-J,4=^7!E
MQQ[;TM6/VOMPK4QAU6FS3W8M1AR3[,>2MI_5#U_X"_53@AF/Y^RMH)6K4Z1J
MDE$2-)U*4EJA*14T196>@0YJ6B)I2Y\"*QUZ88X8'] 4GF-IVGE,<IA?")B8
MB8YQ/.)CQ@ !AD
M
M
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MN7ZDY0RHR['7RGEAN*M:B<WJ5\$.,QOZO[7&5$QV%X!R9@
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M]%J\Y3)Z3J=/COEI^G3<K4)&8AKF1)>=DH\.:E8S'IBUT*/"AO1R8HK45,2
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MZFM":!UG? VI^5@_ZC$D3JJ^'-'\G4_]+F=P( %5UO
M         <47MQ?X*.6K\V);]>4H\PY_X3OYRGIX^W%_@HY:OS8EOUY2CS#G
M_A._G*6+ZG?X!J?RNWU.!6;KM^$-)^1Q]?F6EC^>]"\L?SWH2Y/=*%Y[I=V[
MW33^\[+'^=5EOU+4CMRG4:]TT_O.RQ_G59;]2U([<I4OK"^&-;\K%]1B7%ZL
M?@+A_P C-_U.8 !IC?        '"9[P__!*RE?Y?D_\ _>)98\V!-*]AZ3_O
M#_\ !*RE?Y?D_P#_ 'B66/-@32O861ZG_@W-^69?J=.JWUU_"V#\@Q?7ZE<
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M2>O$.'8\=K1.ITE:X<U9GSK5K&V++Z9B](B+3^$K?U;_ -&"B*5-"2*
M  O  I>5
M
M
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M\^:8]3AOZ/?L+>C[8-8$S-V<F[>56"K7I4+<3GW2EVQ$Q1T*B2<.0HL/-?\
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MW)JU_ SHER<H$1$U=R%;D4X=_L_P%-/ N .;&P  R
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M]OK*0).CY)<NU5;*_1(4"F62RD5"*]T&+!9="DZ-;.9BN<L"+"9U<M(6B?=
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MRG%]']D16,>6E[8\V&)F?)VWWI,3,1,UO28F+3$1VHM$>]ED !JK<
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M        <)GO#_\ !*RE?Y?D_P#_ 'B66/-@32O8>D_[P_\ P2LI7^7Y/_\
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MCOB>4[3"H /@[
M
M
M       %+BH IITH8GLNT=O/FIE5"E^XXSZ888+RUS$4SN9?SSSXXM&DS%MV
M4545+TN^K\%U:N_M*WZ]*77[^Y"2J7I<8%AJGX//?Y>*F66)\-%X\\[C#HT]
M_ERN@SICQV;;BY=BIN#"(K;^.W?S=@8E;J7OT<KSQDNAJG//?I+<._P3=S>!
M#>S9SZ>1@5B:N>SXH3LS6B:]"\-6SN,;FHO'R[0-<Z'NN[EYW>A&?"7'9X?)
M>!M',76E_.SGO,.9KV:O@G=Q UCH6.'.K@O C.AISA]E_<;56;-FCU^!A>S;
MIX?'7<!JG0^WNY7#G01W0L,/2[';I-J^%OWW(FS;\L3 L/LV+V;>&T#4/A8Z
M-EVWTP,+H?V<X\ZS<+#79WZO7O[B.Z%?\_#TN T[F<KY<X=IA="3AQ^>[E#;
MNAZO!=/HN[7P([H?*Z^&KG8!J7P<%P]/7E2.L+L\>=1MUA]FY='/#R,;H>[M
M3Y?/ #2+!W+YIIY^)A6%V<-?.WU-TL'[=&GP[_(CO@KA?V:OE@!IU9AM3ASZ
MJ8704X<,,>'H;AT+G#P5.;C"Z%=PNXIL TSH"[$5-6WGG21W0KK]*)SKYWF\
M6#L\.>>TQ*Q4^>'R TRP^&I.4T7<Z3&K-RIP1><<3<.@IK2[A\3"L#8O9KY3
M5Z@:OJ^/G\]!8L)46]-*:%3!W8[3?P7;<;-TONU=_I\3$Z%MPN7Q^>L#^&M7
M86CUUCH5=H]*K4)[<QS*Q39&J(K?Y*+/R\PYJ;,QR*FJX^'LHGLH>CK:AT2)
M5,DEDH,>-?ULU1I68L_-Q%<MZO?,468DGY]^#7I<Y$P:J(<BZPU[]J:^S@4S
M%V=RZ^'B=S2\0U&#GASYL/S62^/^I,.EJ^':?41,9\&'-$\MLN*F2-O9>LN
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MY7_SXH/[,P#MFE2.G_PQKOEX_J<:Y/5Q\"</^;O]=E  :<W<
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M?9$1^QROEO;WUK6^5:9_;+"B+?CCVW\W_,S 'TB'S1U1>=7QY[N]%[LOT_\
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M[SX4B/!9GJ4U>2^@U.*TS./#J?<M^Z/*4BUZQX;1:.UM'C>9GOWFX $1IG
M
M
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M8NCO0CAW#/.T^")S;;3J,LQDS3$]^UIB(QQ/C&.M(GQW6(Q$+P#5VV@
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M=$N$9-!P[2Z3--+9,-+5M..9FDS.2]_-FU:S,;6COK', !X#8@
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M+EV'I9_>_P!T4_R8P_Z16D_K,?>_W13_ "8P_P"D5I/ZS'VX.&_@=9^CP_\
M?/M*\4_#Z'])G_T[S3+EV"Y=AZ6?WO\ =%/\F,/^D5I/ZS'WO]T4_P F,/\
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MQ+!K,^72VQXHS1:N*^6;SY3#DQQM%L-(Y3:)GSHY>E]E@ A9.H
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MD]]#^#9>'\-TNCS6I;)@KDBUL<S-)[67)DCLS:M9[K1$[UCGN  U]LH
M  #A,]X?_@E92O\ +\G_ /[Q++GFPHBWK@NH]=_I&]':R.56R-2L-;JE)6K,
M5>)3XE0IJS,S*)'?2ZC*U:27Z1)Q8,PSJ9Z2EH]S(C4?U>8^]BN:O&BWW?\
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M@ \%L0
M
M
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MQ4         "EQ4 4N0J                  *7%0    I<5
M         "EQ4 4N%Q4 "EQ4 4N07%0                         *7%0
M   %$0J                                    %+BH
M     I<FPJ *7(5  I<+BH I<5               *7(5  %+BH HA4
M       *7%0 !2Y-A4                              %%0J    %+BH
M            447%0   %+BH            "EQ4 "EQ4
M  "ER%0!2X(A4 4N%Q4 4NW%0         !2Y"H IFIS<+D*@
M
M
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M#&[6]7P[E'5\.Y39=2N_LO\ B.I7_&Y[0;M9U7#N4N2#Q[D^//;>;'JN/?\
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M7:RH!D
M
M
M
M
M
M
M
M
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MD*(J\Z2X=GTL;K4\"X Y&P  R
M
M
M
M
M
M
M
M
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M[E,3.PQHM^C$NS%7=Y^AE1$*F)]7_P "QK+OLYYW%]X*F=O2PH"H,L@
M
M
M
M
M
M
M
M
M
M                    4N*@"EW/-Q2].;RX#9C;_P [U+KT,:P^SGG09 IB
M(V]GH9858J;_  ^1:JW:B1>+D,3,^@W1RF:G*(9U8FPM6'LO3N,S(C]6GV8<
M\WEBP=BDC-79?P^?.H<45!N,*,<FOOYU%GUL?JHN^[42+T%R&1&O3ASL4=O>
MGH2;D+>K;L Q7;T\O,7+L[L2_JDU)SW*6=5=H54[O7[ RI?S<I:MW-WQ0R9K
MMJ^!16NVW]B*#9CS$W<\"BPDV=V'J7K?_)O[$3GYBY?Y//8#9CZE-GC\AU*<
M/'S0OO\ \7S%Z?R>[[ ;+.JWJ.IWJ7WIL=WW%,]-B_\ :!LMZK>HZG>I>KF[
M_P#M!')L=W@V6=3OOYVCJ4V>/R+[T_DJ,[_%\PQLM2$G*_(=6FQ.[YE__4\"
MN:NSPYV 6W)RB?!"Z_FXJB.X=B(%:_;Y!G81%70G?@+EW)V^G.!58:KI5?#9
MCK*I"39X_(,,:JB:5[D4I>F]?#[>4)'5MV%<U RP7KC<V]/&_M+\UUVF[A@9
M;DYQ%Z!A@ZE?Y1>D-.5O\T,J8Z+Q<NPQN*7 N2&N_G?I,B0TV#<8;RY&JNQ/
M$S7(45=G@.?_ )_Y!NLZK:O9J]>!>C;BH&W_ .A4I<5 B!1$*@&2(
M
M
M
M
M
M
M
M
M
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M(
M
M
M
M
M
M
M
M
M
M   *7<WJ+N;U*@,;1Z  !D             4NYO%W-ZE0&-O4  ,@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
#/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
